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ABSTRACT 
CYNTHIA P. HOLLEY: The Dock Family of Atypical Guanine Nucleotide Exchange 
Factors: Regulation by ELMO1 and RhoG 
(Under the direction of John Sondek) 
 
The Dock family of proteins regulates diverse biological processes including cell 
migration, phagocytosis and neuronal polarization.  These proteins contain a unique type 
of guanine nucleotide exchange factor (GEF) domain, and function as GEFs for Rho-
family GTPases.  Several Dock-family proteins form complexes with ELMO proteins and 
the Dock/ELMO complex acts as a bi-partite GEF for Rac. Molecular details of how the 
Dock/ELMO complexes bind and exchange nucleotide on Rac are critical for our 
understanding of their biological effects, yet remain poorly defined.   
As described here, purified Dock2/ELMO1 complex is a stable heterotetramer 
composed of two molecules each of Dock2 and ELMO1.  This heterotetramer 
coordinates a single molecule of nucleotide-free Rac.  We identify an inhibitory 
conformation within ELMO1 mediated through contacts between the N- and C-terminal 
regions of ELMO1 and describe a mechanism for relief of this inhibition through the 
binding of RhoG, another Rho-family GTPase.  The interaction between RhoG and 
ELMO1 is both nucleotide-dependent, and dependent upon the C-terminal polybasic 
region of RhoG.  These data provide fundamentally important molecular insights into the 
composition of the Dock/ELMO complex and regulation of nucleotide exchange via the 
Dock/ELMO proteins.
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CHAPTER 1:  INTRODUCTION 
Small GTPases 
Proteins from the Ras superfamily of small guanosine triphosphatases (GTPases) 
function as binary molecular switches within cellular signaling pathways.  These proteins 
cycle from an inactive GDP-bound state to an active GTP-bound state.  There are over 
150 human proteins within this family, with orthologs in organisms ranging from 
roundworms and fruit flies to slime mold and plants [1].   
Within this larger superfamily, the Rho family of small GTPases comprises one of 
five major branches grouped by sequence similarity [2].  Rho-family GTPases regulate 
cellular signaling pathways that coordinate actin reorganization and gene expression.  
Diverse cellular processes including phagocytosis, adhesion, migration, neurite extension 
and retraction, growth, survival and cell polarization are controlled through intricate 
regulation of these 22 Rho-family GTPases and the numerous effector proteins to which 
they bind [2]. 
Rho-family GTPases are typically located at a membrane within cells, and this 
association is enabled by a four-residue CAAX motif (for C = cysteine, A = aliphatic, X 
= any amino acid) at the C-terminus of the proteins [3].  This motif enables the lipid-
modification of the protein at the cysteine residue which prompts the removal of the final 
three amino acids [3].  A polybasic region often precedes the CAAX motif, and can be 
involved in membrane association as well, through electrostatic interactions with the 
generally negatively-charged phospholipid head groups of the membrane surface [4]. 
As the name implies, small GTPases have intrinsic GTP hydrolysis activity, and 
are capable of self-inactivation through hydrolysis of the gamma phosphate in GTP.  The 
mechanism of activation involves dissociation of the bound GDP molecule, and then 
binding of the more prevalent GTP located within the cytosol [1].  Most small GTPases 
have a higher affinity for GTP compared to GDP.  Two regions within the GTPases, 
called switch 1 and switch 2, change conformations depending upon the bound nucleotide 
[1].  The movement of the switch regions is what allows for binding to effector proteins 
in the GTP-bound state.  The loading of GTP and hydrolysis of GTP occur relatively 
slowly, and thus, a variety of proteins act as catalysts and regulators of the GTPase cycle 
[1] (Fig. 1). 
GTPase activating proteins, or GAPs, increase the intrinsic hydrolysis activity of 
the GTPase by stabilizing the GTPase active site in a conformation needed for hydrolysis 
[5].  The GAPs provide a system of control whereby the GTPases are rapidly inactivated, 
preventing overstimulation of signaling pathways.  Highly transforming mutations in 
GTPases often disable the ability of the GTPase to hydrolyze GTP, or interfere with GAP 
binding [6,7]. 
Guanine dissociation inhibitors, or GDIs, prevent activation of GTPases by 
sequestering the inactive, GDP-bound form through specific binding and removal from 
the membrane [8].  Without proper localization to the membrane, the GTPases are unable 
to function in the proper signaling pathways, and therefore, signaling through those 
pathways is suppressed. 
2 
 
Guanine nucleotide exchange factors, or GEFs, catalyze the exchange of GDP for 
GTP, thereby activating the GTPase, enabling signaling to downstream effectors.  The 
exchange reaction is catalyzed by the destabilization of nucleotide binding caused by the 
GEF, and the exchange of GDP for GTP is driven by the substantially higher ratio of 
GTP:GDP within the cell [9,10].  Once activated, the GTPases are able to bind to 
downstream effector proteins, setting off a chain-reaction-like string of events within the 
cell. 
Guanine Nucleotide Exchange Factors 
Although there are only 22 known human Rho-family members, there are 
approximately four times as many known human GEFs for these proteins [9].  Obviously, 
Rho-family GTPases can function in more than one cellular signaling pathway, and it has 
been suggested that exchange factors can determine in which pathway a specific GTPase 
will act by localization and even acting as a scaffold to bring requisite components of a 
specific pathway together [9].  
The Dbl-family of GEFs is well-studied and the largest of the known Rho-family 
GEFs.  Composed of 69 human members, Dbl-family GEFs can be identified by the 
presence of a Dbl homology (DH) domain followed by a pleckstrin homology (PH) 
domain [9].  Nucleotide exchange is catalyzed by the DH domain, while the purpose of 
the PH domain is less certain.  In some cases, the PH domain participates in the GTPase 
binding surface, and in others it is far removed from the GTPase.  Membrane 
localization, allosteric modulation through phospholipid binding, and protein interactions 
are all suggested roles for the PH domain [9-11]. 
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The mechanism for exchange by Dbl-family GEFs involves significant change to 
the nucleotide-binding pocket of the GTPase caused by the binding of the exchange 
factor to the switch regions [9].  The remodeling of the switch regions destabilizes the 
required Mg2+ ion cofactor (which helps coordinate the nucleotide in the binding pocket) 
which, in turn, destabilizes the nucleotide, allowing for dissociation of GDP and 
subsequent association of Mg2+ and GTP.  This general mechanism is common to the 
Dbl-family GEFs as well as the non-homologous bacterial toxin SopE [9,10].  This 
protein does not have the DH and PH domains of the Dbl-family GEFs, yet the similarity 
of the mechanisms shown by crystal structures would suggest a common mechanism may 
be seen even for other GEFs without a DH domain. 
No Dbl-family GEFs have been identified for plant Rho-family GTPases, or 
Rops.  Instead, a new family of RopGEFs, containing a domain named PRONE (for 
plant-specific Rop nucleotide exchanger) has been identified [12].  These GEFs do not 
possess any sequence homology with the Dbl-family GEFs.  A structure of the PRONE 
domain from RopGEF8 has recently been solved both in isolation and in a complex with 
Rop4 [13].  Although the structure of the PRONE domain is unlike any GEF structure 
solved to date, the mechanism of activation as determined by these structures is similar to 
that seen with Dbl-family GEFs and SopE.  The primary method of catalyzing nucleotide 
exchange involves manipulation of the switch residues of the GTPase to destabilize the 
nucleotide binding pocket [12-14]. 
Other mammalian Rho-family-specific GEFs have been identified that do not 
contain the DH/PH domains of the Dbl-family GEFs.  SWAP-70 and related IBP are 
proteins that contain a PH domain, but lack a DH domain [15-17].  SWAP-70 has Rac1-
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specific GEF activity and lies downstream of phosphatidylinositol 3-kinase (PI3K).  A 
region with low homology to DH domains has been predicted to exist N-terminal to the 
PH domain, but that prediction is not statistically significant.  Alternatively, these 
proteins are predicted to contain a coiled-coil region C-terminal to the PH domain.  These 
atypical GEFs are poorly characterized [9,15-17]. 
SmgGDS is an atypical GEF for Rho-family GTPases.  The literature on this 
particular GEF identifies a number of different Rho and Ras-family GTPase substrates 
for this exchange factor, but recent studies in our lab have determined that SmgGDS is 
specific for RhoA and RhoB [18].  SmgGDS is an armadillo (ARM)-repeat containing 
protein, and has no detectable DH or PH domains.  The polybasic regions of the GTPases 
play an active role in the binding and exchange activity of this particular GEF [18-24]. 
The Dock1-related family of proteins contains 11 mammalian members, with 
orthologs in humans, roundworms, slime mold, fruit flies, yeast and plants, among others 
(referred to as the Dock family of proteins in the rest of this document) [25-29].  This 
family also contains no obvious homology to the Dbl-family GEFS, but are, instead, 
defined by two regions of homology within the family, DHR-1 and DHR-2 for Dock 
homology region 1 and 2.  The DHR-2 region is the center of exchange activity for these 
atypical exchange factors for Rho-family GTPases.  While these proteins have been 
shown to be bona fide GEFs, information on how these proteins are regulated is relatively 
sparse and the mechanism by which they catalyze exchange is still unknown [9,27,28].  
The Dock family has been grouped into four different subfamilies (Fig. 2), based on 
sequence identity over the entire sequence of the proteins, with 50-65% sequence identity 
between subfamily members[26,27,29].  The following sections review each subfamily. 
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Dock-family GEFs 
Dock A subfamily: Dock1, Dock2 and Dock5 
The Dock A subfamily of proteins includes two of the most well-studied of the 
Dock-family proteins, Dock1 and Dock2.  This subfamily has several features in 
common.  The domain structure consists of the typical Dock-family DHR-1 and DHR-2 
regions, along with an N-terminally located SH3 domain and a C-terminally located, 
variable proline and serine-rich region in most members [26-29].  Rac is the known Rho-
family GTPase substrate for two of the three proteins within the Dock A subfamily [26-
29]. 
Dock1, originally identified as Dock180 (for 180-kDa protein downstream of 
Crk), is a prototype member of the Dock family of proteins [30,31].  Identified as a 
binding partner for the SH2 and SH3-domain containing adaptor protein, Crk, Dock1 
mRNA was expressed strongly in the placenta, lungs, kidneys, pancreas and ovaries than 
in the thymus testes and colon.  In contrast, expression was not detected in blood cells, 
suggesting that Dock1 was expressed only in adherent cells [30].  Subsequent analysis 
found that Dock1 association with CrkII was stimulated by integrin in NIH3T3 cells and 
that this binding correlated with CrkII binding to p130Cas, a protein that localizes to 
focal adhesions [32].  Consequently, coexpression of p130cas and CrkII with Dock1 
induced local membrane spreading and accumulation of complexes containing 
Dock1/CrkII/p130cas at focal adhesions.  The C-terminal proline and serine-rich region 
of Dock1 was determined to be necessary for the Dock1-CrkII interaction [30,32]. 
Dock1 was found to increase active Rac1 in cells and was capable of direct 
interaction with Rac1, but not Cdc42 or RhoA, and Dock1-induced membrane spreading 
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was inhibited by dominant-negative Rac1 [33].  Two homologs of Dock1 in Drosophila 
(myoblast city, MBC) and C. elegans (ced-5) were identified, and were grouped into a 
family of proteins, CDM, for ced-5, MBC, and Dock180 [31].  This family of proteins 
was suggested to be an evolutionarily conserved family involved in the extension of cell 
surfaces.  MBC was necessary for dorsal closure and myoblast fusion in Drosophila 
embryos [34], and ced-5 was necessary for cell corpse engulfment and distal tip cell 
migration [31].  The αvβ5 integrin was shown to mediate phagocytosis of apoptotic cells 
through recruitment of the Dock1/CrkII/p130cas complex, which in turn triggered Rac1 
activation and phagosome formation [35].  A later study demonstrated that a secreted 
glycoprotein, MFG-E8 which can bind phosphatidylserine (PS) on apoptotic cells, is a 
ligand for the αvβ5 integrin, and can trigger activation of Rac1 through Dock1 for 
phagocytosis of apoptotic cells [36]. 
The identification of Dock1, and determination that it and its homologs 
participated in the activation of Rac1 and extension of cell surfaces paved the way for 
identification of Dock1 and homologs as Rho-family specific GEFs.  The ability to 
directly activate Rac1 by a portion of Dock1 called the Docker domain led to the 
proposal that Dock1 was an atypical, non-Dbl-family Rac-specific GEF [25].  About the 
same time, the other mammalian members of the Dock-family of proteins were identified 
through homology searches, and several were shown to have direct GEF activity on Rho-
family GTPases [26,28].  The Docker domain was found to be within a region of 
homology between the family members and was named DHR-2 [26] or CZH-2[28].  
Another region of homology between the Dock-family proteins was N-terminal to the 
DHR-2 region, and was named DHR-1 [26], or CZH-1 [28].  Dock1 and its homolog, 
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MBC, can bind phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) through the DHR-1 
region.  This binding mediates localization of Dock1 to the membrane [37-39]. 
The ELMO (ced-12) family of proteins were identified as Dock1/ced-5 binding 
partners [25,40].  These proteins were shown to functionally cooperate with Dock1, 
although they had no exchange activity alone, leading to the suggestion that the 
Dock1/ELMO complex functioned as a bipartite GEF for Rac1 [25].  This finding was 
not universally accepted, as Dock1 was capable of acting as an exchange factor in vitro 
without ELMO1 [27,38].  Also, it was found by some groups that efficient activation of 
Rac1 by Dock1 required ELMO1 in cells [25,41], and others found the ELMO1 
interaction dispensable [26]. 
Interactions between Dock1 and ELMO proteins include at least two direct 
interactions between the N-terminal 350 residues of Dock1 and the C-terminal 100 
residues of ELMO1, with one of those interactions involving the Dock1 SH3 domain and 
the ELMO1 PxxP motif [25,41,42].  Separate from these interactions, the isolated PH 
domain of ELMO1, although missing the regions of ELMO1 necessary for direct 
interaction with Dock1, is capable of binding, in trans, to a complex of Dock1 and Rac1 
[41].  This interaction between the PH domain and the Dock1/Rac1 complex is capable of 
enhancing the exchange activity of Dock1.  It was suggested that the PH domain 
stabilizes the nucleotide-free transition state of Rac1 bound to Dock1, allowing for 
enhanced exchange activity[41].  The SH3 domain of Dock1 is also capable of binding to 
the DHR-2 region of Dock1 and competing for binding with Rac1 [42].  This SH3/DHR-
2 interaction is relieved upon binding of ELMO1.  The authors suggested this was an 
inhibitory mechanism for regulation of the Dock1 molecule, although it is unclear if the 
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two proteins exist separately within cells [42].  The assembly of the Dock1/ELMO 
complex may be regulated by the C-terminal SH3 domain of CrkII [43].  Endogenous 
Dock1/ELMO complex has been immunoprecipitated from HeLa and CHO-K1 nuclear 
extracts using an anti-Dock1 antibody [44].  The resulting Dock1/ELMO complexes 
contained more than one Dock1 molecule and more than one ELMO molecule per 
complex.  The isoform of ELMO (1, 2 or 3) immunoprecipitated with Dock1 depended 
on the cell line.  Multiple isoforms of ELMO1 were precipitated with Dock1 in each cell 
line [44]. 
Other functions for the interaction between Dock1 and ELMO proteins are 
evident.  ELMO1 is capable of inhibiting ubiquitylation of Dock1, thereby protecting 
Dock1 from degradation [45].  Brain-specific angiogenesis inhibitor 1 (BAI1), a PS-
sensitive receptor, can interact with the Dock1/ELMO1 complex through ELMO1 [46].  
Recruitment of Dock1/ELMO1 to the BAI1 receptor mediates phagocytosis of apoptotic 
cells.  RhoG, another Rho-family small GTPase has been shown to bind specifically to 
the N-terminus of ELMO1 in a GTP-dependent manner [47].  This interaction can 
localize Dock1/ELMO1 to the plasma membrane.  Activation of Rac1-mediated cell 
migration is mediated by RhoG through the Dock1/ELMO1 complex.  Interestingly, the 
interaction of Dock1 with CrkII is dispensable for this function [48].  Phagocytosis of 
apoptotic cells is also mediated by this interaction, and this mechanism is conserved in C. 
elegans as well as humans [49].  The interaction between RhoG and ELMO1 is exploited 
by the bacterial pathogen, Shigella.  The bacterial-produced IpgB1 protein binds to 
ELMO1 in a manner mimicking RhoG, and activates production of membrane ruffles 
through the Dock1/ELMO complex, enabling bacterial entry into epithelial cells [50]. 
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The Dock1/ELMO complex has also been implicated in other pathways 
promoting cell motility.  A recent study implicates Dock1 in mediating attractive 
responses by neurons to netrin-1, an axon guidance cue [51].  It has also been reported 
that the Dock1/ELMO complex mediates the activation of Rac1 by ARNO, a GEF for the 
ADP-ribosylation factor 6 (ARF6) at the leading edge of migrating cells [52]. 
Despite the multitude of interacting proteins and pathways in which Dock1 is 
involved, it is clear that Dock1 is active in pathways that promote cell migration and 
phagocytosis within adherent cells.  The evidence that ELMO proteins are a key 
component of Dock1 activity whether by direct activation or indirect activation through 
localization and protein binding is also clear. 
Dock2 was identified through homology to Dock1, and the expression pattern of 
Dock2 in tissues is nearly opposite that of Dock1 [53].  While Dock1 is present in mostly 
adherent cells, Dock2 is expressed mainly in non-adherent, hematopoietic cells.  Dock2 
mRNA expression was detected in peripheral blood cells, with slight expression in spleen 
and thymus.  Dock2 was expressed only in lymphocytes and macrophages of various 
organs as detected by immunostaining of human cadaver tissue [53].  Dock2 is a specific 
exchange factor for Rac1, and does not activate Cdc42 or RhoA and is at least capable of 
binding to Rac2 [26,53]. 
Unlike Dock1, Dock2 does not bind to CrkII.  It does, however, associate with a 
hematopoietic-specific Crk-like protein, CrkL, which can induce activation of Rac1 [53].  
Interruption of this interaction inhibited CrkL activation of Rac1.  Dock2 is essential for 
lymphocyte chemotaxis [54].  In Dock2-deficient cells, Rac activation and actin 
polymerization induced by chemokines was nearly abolished. 
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ELMO proteins are capable of interacting with Dock2, and this interaction is 
critical for Dock2/ELMO1-mediated Rac1 activation[55].  For instance, expression of 
Dock2 in T-hybridoma cells lacking endogenous Dock2 induced Rac activation and actin 
polymerization.  In addition, expression of a Dock2 mutant incapable of binding ELMO1 
failed to effect these changes [55].  In plasmacytoma cells expressing Dock2 but not 
ELMO1, expression of ELMO1 induces Rac activation [55]. 
Dock2 has been implicated in a variety of processes critical for the survival of 
hematopoietic cells.  For instance, Dock2 is essential for the activation of Rac1 required 
for the formation of immunological synapses mediated by T-cell receptors [56].  In this 
case, Dock2 regulates antigen-induced translocation of T-cell receptors and lipid rafts 
during synapse formation.  Similarly, deletion of Dock2 has been shown to suppress 
cardiac allograft rejection by eliminating lymphocyte homing and immunological 
synapse formation [57].  Furthermore, chemokine-stimulated adhesion of lymphocytes 
under shear stress requires Dock2 for efficient attachment to VCAM-1 [58].  Vav1, a 
Dbl-family GEF that specifically activates Rac GTPases, is also required for this process, 
but the interplay between Vav1 and Dock2 is not well understood.  Dock2 expression is 
also required for development of mouse Vα14 natural killer T cells [59], which play 
important roles in host defense against pathogens, immune regulation, and tumor 
surveillance.  Dock2 is necessary for another type of T-cell differentiation in CD4+ T 
cells.  Dock2 links T-cell receptor signals to IL-4Rα downregulation to control lineage 
commitment of these cells [60].  Finally, spingosine-1-phosphate-mediated egress of 
lymphocytes from peripheral lymph nodes and interstitial mobility of lymphocytes also 
depend on Dock2 [61]. 
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Considering the importance of Dock2 in hematopoietic cells as discussed above, it 
is unsurprising that the Dock2/ELMO1 machinery has been taken advantage of by a 
pathogen.  The HIV-1 protein Nef, a potent virulence factor, can form a complex with 
Dock2/ELMO1, and this interaction is dependent upon ELMO1 [62].  Nef activates Rac 
in T cell lines and in primary T cells, and the authors suggest that Nef modulates multiple 
aspects of T cell function through the Dock2/ELMO1 complex [62]. 
The variety of studies showing the necessity of properly functioning Dock2 in 
lymphocytes serves to highlight the fact that Dock2 is critical for regulation of the actin 
cytoskeleton and mobility within hematopoietic cells.  The specific contributions of 
ELMO proteins within the context of the Dock2/ELMO complex remain to be 
determined. 
Very little is known about mammalian Dock5, as it has not yet been cloned.  Out 
of 65 Dbl-family GEFs and 11 Dock-family GEFs tested, only Dock5 and Net1, a Dbl-
family GEF, were up-regulated during RANKL-induced osteoclastogenesis [63].  In this 
case, silencing of Dock5 in RAW264.7 cells was found to be extremely cytotoxic, 
although it had no apparent effect in NIH3T3 fibroblasts.  The zebrafish ortholog of 
Dock5 was cloned and used to design morpholino oligonucleotides to block the function 
of the protein in zebrafish embryos[64].  In this study, morpholino embryos for Dock5 
showed defective fast-myoblast fusion.  Dock1, Dock5, Crk and CrkL were all tested 
similarly, and when different combinations of Dock and Crk proteins were tested, the 
highest level of fusion suppression observed occurred in embryos injected simultaneously 
with Dock5 and CrkL morpholinos. 
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Dock B subfamily: Dock3 and Dock4 
The Dock B subfamily consists of two mammalian members, Dock3 and Dock4.  
This branch of the family is most similar to the Dock A proteins, with Dock C and Dock 
D proteins further removed by sequence homology.  The Dock B proteins are about 56% 
identical within the subfamily, but are only about 40% identical to Dock A subfamily 
members [26,28].  Like the Dock A members, however, Dock B proteins contain an N-
terminal SH3 domain, which allows association of ELMO1. 
The presinilin (PS) gene is linked to approximately 50% of familial Alzheimer’s 
disease (AD) cases [65,66].  Dock3 (also modifier of cell adhesion – MOCA) was 
identified through yeast-two hybrid screens as a protein capable of interacting with 
presinilin1(PS1) and labeled as PBP, or presinilin binding protein [67].  This interaction 
was confirmed with immunoprecipitation of the two proteins from transfected 
mammalian cells.  Following up on this interaction, the authors discovered that co-
expression of Dock3 and PS1 localized primarily cytoplasmic Dock3 to a discrete, 
organelle-like compartment, likely the endoplasmic reticulum, where PS1 is primarily 
localized.  Dock3 mRNA was only found in the brain and spinal cord, highly expressed 
in the cerebral cortex and hippocampus, and the level of Dock3 in the soluble fraction of 
AD brains was reduced compared to age-matched normal brains [67].  A later study 
found that Dock3 is associated with intracellular neurofibrillary tangles (NFT) and 
expression increases phosphorylation of the NFT protein, tau, suggesting that Dock3 may 
play a role in the AD neurodegenerative process [68].  Further study showed that 
expression of Dock3 decreased amyloid precursor protein (APP) and amyloid β-peptide 
secretion, and reduced cell-substratum adhesion, likely through direction of APP to the 
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proteasome for degradation [69].  Another study identified the Dock3 gene as one of two 
genes disrupted by a pericentric inversion on chromosome 3 associated with an attention 
deficit hyperactivity disorder (ADHD)-like phenotype [70]. 
Dock3 has been shown to bind to Rac1, to enhance Rac1 activation, and to 
promote Rac1-dependent cell migration [71,72], but it does not interact with RhoA or 
Cdc42 [72].  In addition Dock3 interacts with ELMO1, and co-expression of Dock3 and 
ELMO1 is necessary for the promotion of Rac1-dependent cell migration [71].  
Membrane-targeted Dock3 also enhances GTP-loading of Rac1 and JNK activation in 
cells, and endogenous Dock3 co-localizes with F-actin at the leading edge of lamellipodia 
[72].  It was determined that Dock3 promotes cell-cell adhesion and neurite outgrowth 
mediated by N-cadherin [69]. 
The Dock4 gene was identified as a homozygous deletion a mouse osteosarcoma 
cell line, and was mutated in a subset of human cancer cell lines [73].  In this study, 
restoration of wild-type Dock4 in the Dock4-null osteosarcoma lines restored contact 
inhibition, reduced colony formation in soft agar and formed small, non-invasive tumors 
when injected into nude mice, as compared to the Dock4 null cell line which formed 
large invasive tumors.  The authors also reported that cells lacking Dock4 fail to form 
adherens junctions and this phenotype could be rescued by expressing Dock4 or by 
expressing constitutively active Rap1.  Expression of Dock4 and dominant negative Rap1 
failed to promote the formation of adherens junctions.  In addition, Dock4 was shown to 
promote activation of Rap1 in transfected cells [73].  Other studies, however, describe 
Dock4 as a Rac1 activator, and were unable to detect Rap1 activation by Dock4 [42,74].  
Dock4 was able to interact with ELMO1, and expression of active RhoG induced 
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translocation of the Dock4/ELMO1 complex to the plasma membrane from the 
cytoplasm [74].  This translocation enhanced the Dock4/ELMO1-dependent Rac1 
activation and cell migration, and knockdown of Dock4 expression reduced cell 
migration.  Dock4 is expressed in multiple tissue types, with the highest expression noted 
in skeletal muscle, prostate and ovary [73,75].  An isoform of Dock4, alternatively 
spliced in the C-terminus, is a strong Rac activator and is expressed in the brain, inner ear 
and eye tissues [75].  This isoform interacts with harmonin and is present in the hair 
bundles of auditory sensory cells. 
Dock C subfamily: Dock6, Dock7 and Dock8 
The Dock C subfamily of the CDM proteins has the least amount of information 
available about its representative members.  Unlike both the Dock A and Dock B 
subfamilies, these proteins have not been shown to interact with ELMO proteins.  The 
domain structure for these proteins is also not well known, with the only described 
domains being the DHR-1 and DHR-2 regions [27,29] and a predicted coiled-coil motif 
in the C-terminus [9]. 
Dock6 is reported to activate Rac1 and Cdc42, but is otherwise poorly understood 
[76].  For instance, full-length Dock6 or its isolated DHR-2 region immunoprecipitated 
from HEK293T cells activated Rac1 and Cdc42, but not RhoA.  Similarly, the DHR-2 
region activated Rac1 and Cdc42 in cells and promoted associated filopodia and 
lamellipodia [76].  However, unlike other Dock family members, Dock6 did not bind 
ELMO1, ELMO2 or CrkII [76].  Dock6 might regulate neuronal processes since its 
expression is highly increased upon differentiation of mouse N1E-115 neuroblastoma 
cells and Dock6 can regulate neurite outgrowth through Rac1 and Cdc42 [76]. 
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Initial attempts to characterize the GTPase specificity of Dock7, also named 
zizimin-related 2 (Zir2) failed to show significant activation of either Rac1, Cdc42 or 
RhoA.  The protein used for these assays, however, was in vitro translated, and only 
consisted of the DHR-2 region of the protein [26].  Later results identified Dock7 as a 
binding partner for TSC1 or hamartin, a protein that, when mutated, causes tuberous 
sclerosis (TSC) – a disease characterized by development of benign tumor-like 
“hamartomas” in kidneys, heart, skin and brain.  TSC2, or tuberin, forms high affinity 
dimers with hamartin, and can interact with and act as a GAP for Rheb, a Ras-family 
small GTPase.  It was suggested that Dock7 might be a Rheb-GEF, given this linkage of 
interactions [77,78].  More recent studies, though, have elegantly described Dock7 as a 
Rac specific GEF that is highly expressed in the developing rat brain, specifically in 
hippocampal neurons [79].  In unpolarized hippocampal neurons, Dock7 is 
asymmetrically distributed, and is selectively expressed in the axon.  Dock7 expression 
can be manipulated to affect axon formation, with over-expression mediating formation 
of multiple axons and knockdown inhibiting axon formation.  Interestingly, Dock7 and 
Rac activation leads to inactivation of a microtubule destabilizing protein, 
stathmin/Op18, through phosphorylation [79].  Following a trend in lipid binding seen in 
other Dock-family proteins, PI(3,4,5)P3 is produced in the developing axon, and PI 3-
kinase inhibitors abrogated the ability of Dock7 to form multiple axons [79] suggesting 
that the DHR-1 domain of Dock7 may also be capable of interacting with 
phosphoinositides.  Cote and Vuori [27] make an interesting point that stathmin was 
identified as a gene regulating border cell migration in Drosophila oogenesis [80].  
Myoblast city, the Drosophila Dock1 homolog, is also critical in border cell 
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migration[81].  Perhaps regulation of microtubules could be a common effect of different 
Dock-family proteins. 
Dock8 (Zir3) was identified in a yeast two-hybrid screen as a Cdc42-interacting 
protein, and subsequent northern blot tissue analysis revealed a relatively ubiquitous 
expression pattern including placenta, lung, kidney and pancreas, with relatively low 
expression in heart, brain and skeletal muscle [82].  Subsequent immunofluorescence 
staining of cells showed that endogenous as well as over-expressed Dock8 was present at 
edges undergoing lamellipodia formation.  Transfection of a C-terminal fragment (1179-
1701) resulted in ring-like vesicular structures that contained filamentous actin [82].  
Additional yeast two-hybrid assays demonstrated binding between Dock8 residues 1044-
1701, which includes the DHR-1 domain and both activated (61L) and inactive (N17) 
Cdc42 and Rac1, but not activated RhoA  [82].  This Dock8 fragment also interacted with 
TCL and TC10 – Rho-family GTPases closely related to Cdc42.  An assay using 
immunoprecipitated Dock8 1179-1701, however, failed to bind to active or inactive GST 
fusions of Rac1, Cdc42 or RhoA.  This same fragment was tested for binding to GTPases 
in a filter binding assay, and no interaction was detected [82].   
A homozygous deletion of the locus for Dock8 was found in a lung cancer cell 
line [83].  Subsequent analysis of primary lung cancers revealed 87% had reduced Dock8 
expression levels compared with normal cells.  Homozygous deletions of Dock8 were 
also found in a gastric and a breast cancer cell line.  The reductions in gene expression 
occurred regardless of histological type, suggesting that the reductions may be caused by 
DNA methylation or histone deacetylation [83].  Furthermore, Takahashi, et al. suggested 
that the “down-regulation of Dock8 by epigenetic mechanisms is involved in the 
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development and/or progression of lung cancer” [83].  Dock8 was originally described as 
1701 amino acids in length [82]; however, later work proposed a version (2099 residues) 
with an extended N-terminus [83] and most rece3nt work suggests that Dock8 contains 
2033 residues [84].  Disruptions of the Dock8 gene have also been found in two unrelated 
patients with mental retardation [84]. 
Dock D subfamily: Dock9, Dock10 and Dock11 
Proteins in the Dock D subfamily of Dock proteins contain the typical DHR-1 and 
DHR-2 regions, but, like the Dock C subfamily, this group does not contain the N-
terminal SH3 domain of the Dock A and B subfamily members [26,28,29].  As expected 
with the lack of an SH3 domain, proteins in this subfamily do not interact with ELMO 
proteins.  The Dock D proteins, however, do contain a PH domain in the N-terminal 
region [26,28,29].  Two of the three mammalian proteins in this subfamily have been 
identified with specificity for Cdc42 over other Rho-family GTPases.   
Dock9, also named zizimin1, is the most-studied protein of this subfamily.  
Originally identified in a screen for proteins that specifically interacted with nucleotide-
depleted Cdc42 and were eluted by the addition of GTPγS, Dock9 was precipitated from 
NIH3T3 cells, human umbilical vein endothelial cells, rat vascular smooth muscle cells 
and COS-7 cells [28].  Interestingly, one group discovered that Dock9 mRNA levels were 
highest in brain lung and kidney, while levels in the heart, liver, skeletal muscle and 
hematopoietic organs were low [85].   Another group discovered a slightly different 
mRNA distribution where levels were highest in heart and placenta, with relatively high 
levels in kidney, brain, lung and skeletal muscle and low levels in liver, intestine and 
hematopoietic tissues[28]. 
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 The protein was named zizimin1 (from the Hebrew word for spikes), reflecting 
its ability to induce microspike formation when over-expressed in fibroblasts, a function 
linked to Cdc42 activation [28].  Dock9 was shown to interact directly with Cdc42, but 
not Rac1 or RhoA [26,28,85] and to require the DHR-2 domain for its exchange activity.  
Deletion of the N-terminus of Dock9 resulted in a stronger interaction with nucleotide-
depleted Cdc42 [28].  Full-length Dock9 is capable of activating Cdc42 within cells, and 
the isolated DHR-2 region is capable of activating Cdc42 in vitro, but is not efficient at 
activating Cdc42 within cells [26,28].  When cells were co-transfected with the DHR-2 
region and with a cytoplasmic form of Cdc42, the DHR-2 region seemed fully active on 
Cdc42 [28].  The authors suggested that the N-terminal PH domain may function in 
membrane association, and the lack of the PH domain in the DHR-2 did not allow the 
protein to localize properly to activate Cdc42. 
Building upon the observation that N-terminal truncations of Dock9 interacted 
more strongly with Cdc42, Meller and colleagues [86] found that three regions within the 
N-terminal portion of Dock9 are capable of interaction with the DHR-2 region.  The 
DHR-1 region, the region N-terminal to the PH domain, and a region C-terminal to the 
PH domain were all capable of interaction with the DHR-2 region.  The interaction 
between the N- and C-terminal regions of Dock9 inhibited Cdc42 binding.  Analysis of 
Dock9 by limited proteolysis, suggested that the DHR-2 homology region might not be a 
complete structural domain, and that residues beyond the homology region may be a part 
of the GEF domain of the protein [86]. 
Homology between Dock-family proteins was used to identify Dock10 (also 
named zizimin3) [26,28].  This protein has yet to be fully cloned, but expression analysis 
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indicates that Dock10 is enriched in the brain, lung, spleen and thymus [85].  
Additionally, the DHR-2 domain of Dock10 was cloned and expressed in COS-7 cells, 
and lysates were incubated with various nucleotide-depleted GTPases bound to beads 
[85].  The beads were washed and then bound proteins were eluted with GTP.  The DHR-
2 domain of Dock10 associated weakly with nucleotide-depleted Cdc42 and TCL, and 
even more weakly with TC10 and RhoA.  There was no detectable interaction with Rac1 
[85].  Dock10 was also found to be up-regulated in some aggressive, poorly differentiated 
papillary thyroid carcinoma specimens [87]. 
Dock11 (also named activated Cdc42-associated GEF (ACG) [88] and zizimin2 
[28]) was identified through homology to other Dock-family members [26,28], and was 
later cloned as a gene expressed at higher levels in germinal center B cells than non 
germinal center B cells [85].  Expression was detected primarily in hematopoietic organs, 
with low-level expression in some non-hematopoietic tissues.  The C-terminal two-thirds 
of Dock11, as well as the smaller DHR-2 domain were sufficient for binding to 
nucleotide-depleted Cdc42, but the DHR-2 domain does not interact with TC10 or TCL.  
Full-length Dock11 and the isolated DHR-2 domain can both activate Cdc42 in cells [85]. 
Immunoprecipitation assays utilizing GST-Cdc42 as a pull-down matrix identified 
Dock11 as a binding partner, but surprisingly, it was binding preferentially to active 
Cdc42 (Q61L), not nucleotide-free GTPase [88].  In contrast, the isolated DHR-2 domain 
of Dock11 bound preferentially to the nucleotide-depleted form of Cdc42.  The full-
length form of Dock11 was an active GEF for Cdc42, while the DHR-2 domain only 
showed weak activity.  Furthermore, deletion of the N-terminal 272 amino acids of 
Dock11 changed the binding preference from Cdc42 (Q61L) to nucleotide-depleted 
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Cdc42 (T17N).  The essential region for binding active Cdc42 was determined to be 
within residues 66-126 of Dock11, N-terminal to the PH domain [88].  These residues 
(10-127) were capable of binding to the DHR-2 domain, and that interaction was 
increased in the presence of active Cdc42, but not nucleotide-free Cdc42.  A deletion of 
the N-terminal 126 amino acids, abrogating interaction with active Cdc42 also severely 
impaired GEF activity.  The authors proposed a positive feedback model where the N-
terminus of Dock11 binds the DHR-2 domain and this form has weak GEF activity.  
Activation of Cdc42 allows the active GTPase to interact with the N-terminal region and 
the DHR-2 domain, enhancing the activity of the GEF [88].   
A second study examined the interaction between Dock11 and Cdc42 and found 
that while full-length Dock11 did bind GTP-Cdc42, it bound preferentially to the 
nucleotide-depleted Cdc42 [86].  The authors of this second paper suggest that the 
discrepancy between the two sets of results could arise from the differences between the 
Cdc42 proteins used.  In the first paper, Cdc42 mutants were utilized for their activated 
(Q61L) and nucleotide-depleted (T17N) forms [88], while in the second paper, the Cdc42 
proteins were treated with EDTA, nucleotides and MgCl2 to get the desired nucleotide 
state of the protein [86]. 
Dock-family GTPase recognition 
Most studies have focused on assessing the capacity of Dock-family members to 
directly activate specific GTPases.  In contrast, there are limited studies addressing the 
structural determinants within Dock-family members required for the engagement and 
activation of specific GTPases.  A recent study, however, has compared the binding 
properties of the Rac-specific Dock2 and Cdc42-specific Dock9 [89].  By using a 
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multitude of chimeras of Rac2 and Cdc42, as well as point substitutions, the authors have 
been able to map important residues for recognition of cognate GTPases by Dock2 and 
Dock9 [89].  Dbl-family GEFs can discriminate between Rac1 and Cdc42 based on the 
β2 and β3 strands of the GTPase [90,91].  Substitution of tryptophan 56 in Rac1 to the 
phenylalanine of Cdc42 and vice versa is sufficient to change the specificity of Dbl-
family GEFs Tiam1 and ITSN.  For example, Rac-specific Tiam1 is unable to catalyze 
exchange on Rac1 (W56F), but Cdc42-specific ITSN is capable of catalyzing exchange 
on this mutant [92].  The reverse holds true for Cdc42 (F56W), where Tiam1 is capable 
of catalyzing exchange but ITSN loses that ability [93].  Dock2 and Dock9 utilize the β3 
strand of the GTPase for substrate recognition as well.  Similar to the Dbl-family GEFS, 
the Dock-family GEFs gain the ability to catalyze exchange on non-cognate GTPases 
upon mutation of the GTPase residue 56.  However, neither Dock2 nor Dock9 lose the 
ability to catalyze exchange on their mutated cognate GTPase [89].  This suggests that 
while the determinants for GTPase recognition and specificity for Dock-family GEFs 
overlaps to some extent with the Dbl-family GEFs, there are additional determinants for 
Dock-family GTPase recognition.  Emphasizing this, the divergent residues at positions 
27 and 30 within the switch 1 regions of Cdc42 and Rac1 are important for substrate 
recognition by Dock2 and Dock9, while these residues are usually not utilized for 
substrate discrimination by Dbl-family GEFs [89]. 
Concluding remarks 
Identification and characterization of the relatively new Dock family of proteins is 
still a work in progress.  As a consequence, an understanding of how these proteins 
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function and are regulated is very limited.  What is evident is that these proteins play 
crucial roles in the regulation of Rho GTPases and their effectors.  Identification of 
functional and regulatory mechanisms for the Dock-family GEFs will give us insight, 
both into the general mechanisms of Rho-family GTPase activation, and into the specific 
ways in which these Dock-family GEFs coordinate multiple signals and resultant 
outcomes within cells. 
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 Figure 1: Overview of the Rho-family GTPase cycle. 
Rho GTPases cycle from an inactive (GDP-bound) state to an active (GTP-bound) state with the help of 
regulatory proteins.  Active GTPase is capable of binding downstream effector proteins.  GEF: guanine 
nucleotide exchange factor, GAP: GTPase accelerating protein, GDI: guanine dissociation inhibitor, Pi: 
inorganic phosphate, GDP: guanosine 5’-diphosphate, GTP: guanosine 5’-triphosphate. 
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Figure 2: Overview of the Dock family of proteins (mammalian). 
The Dock family of proteins can be subdivided into four groups based on sequence homology, Dock A, B, 
C, and D.  Center: a cladogram showing the relative homology between Dock-family members.  The 
typical domain structures for each subfamily is shown next to its grouping on the cladogram.  DHR-1: 
Dock homology region 1, DHR-2: Dock homology region 2, SH3: Src-homology 3 domain, PH: pleckstrin 
homology domain. 
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CHAPTER 2 – DOCK2/ELMO1: MOLECULAR INTERACTIONS OF A 
HETEROTETRAMERIC GEF 
Background 
The Dock family of guanine nucleotide exchange factors (GEFs) is evolutionarily 
conserved in eukaryotes ranging from mammals to plants and yeast [25,29,94].  
Encompassing 11 mammalian members, the Dock-family proteins are critical for a 
variety of biological processes.  In C. elegans, CED-5 is essential for distal tip cell 
migration and clearance of apoptotic bodies [31].  Mutations within MBC, the 
Drosophila homolog, are linked to developmental defects including improper myoblast 
fusion and problems with thoracic and dorsal closure [34,95].  In mammals, Dock1 (also 
named Dock180) has an important role in apoptotic cell engulfment and cell migration 
[25,35,40,71], while Dock2, primarily expressed in hematopoietic cells, is essential in T-
cell activation and chemotaxis [54,56], and is involved in HIV-1 infection [62].  The 
neuronally-expressed Dock3 regulates N-cadherin-mediated cell-cell adhesion and 
neurite outgrowth [69,70,72], and is potentially linked to Alzheimer’s disease and 
attention-deficit hyperactivity disorder (ADHD) [70,96].  Dock4 was identified in a 
screen for genes deleted in tumor progression, and can act as a tumor suppressor [73].  
The Dock C and Dock D subfamilies (Dock6 – Dock8, and Dock9 – Dock11) have less 
well-defined functions, although Dock7 plays a role in axon specification [27,29,79]. 
Dock-family proteins activate Rho-family GTPases by catalyzing the exchange of 
GDP for GTP; GTP-bound GTPases directly engage downstream effectors to modulate 
their activities.  The relatively new family of Dock proteins varies significantly from the 
well-studied Dbl-family GEFs which utilize a tandem Dbl homology (DH) domain and 
pleckstrin homology (PH) domain to catalyze nucleotide exchange [9].  The Dock family 
of proteins, instead, relies upon a unique region, the docker-homology-region-2 (DHR-2, 
also named “Docker” or “CZH2”) for catalytic activity [25,26,28].  This region of 
homology between the Dock-family members possesses no obvious sequence or 
predicted structural homology to the DH and PH domains of the Dbl-family GEFs and, 
therefore, may function in a unique manner. 
Several of the Dock-family members are known to form a complex with ELMO 
proteins [71,74].  The interaction between Dock1 and ELMO1 is critical for phagocytosis 
of apoptotic cells and for cellular migration [25,41,47,49,55,71,97,98].  ELMO proteins, 
which exist as three mammalian isoforms (1, 2 and 3), have no GEF activity alone, but it 
has been proposed that together, Dock and ELMO proteins function as bipartite GEFs – 
with ELMO proteins aiding in the stabilization of Rac1 in a nucleotide-free transition 
state [25,41,71].  Understanding how Dock and ELMO proteins interact should lead to a 
better comprehension of the functional consequences of this association.   
Of the Dock-family proteins, only the Dock A and Dock B subfamilies have been 
shown to interact with ELMO proteins [71,74].  Through examination of deletion 
constructs and mutational analysis, the interactions between Dock1 and ELMO1 are 
known to involve at least three separate regions: (1) the N-terminal SH3 domain of 
Dock1 and a polyproline (PxxP) motif in the C-terminus of ELMO1; (2) the N-terminal 
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357 residues of Dock1 and the C-terminal 100 residues of ELMO1, likely within the 
residues between the end of the PH domain and the beginning of the PxxP motif and (3) 
the PH domain of ELMO1 binds to a Dock1/Rac1 complex in trans [41,42].  Disruption 
of the first two interactions is necessary to prevent formation of the Dock1/ELMO1 
complex.  Deletion of the SH3 domain or the PxxP motif is not sufficient to eliminate the 
interaction between Dock1 and ELMO1.  A mutation of glycine 171 to glutamic acid 
(G171E) in the N-terminus of Dock1 is sufficient to disrupt the second interaction.  When 
combined, the deletion of the SH3 domain and the G171E mutation can fully eliminate 
the direct interaction between Dock1 and ELMO1.  Alternatively, termination of ELMO1 
at residue 629 prevents formation of the complex, presumably by removing the sites for 
both interactions [42].  Interestingly, the binding of the PH domain of ELMO1 in trans to 
a complex of Dock1 and Rac1 increases the exchange activity of Dock1.  It has been 
proposed that the PH domain aides in the stabilization of nucleotide-free Rac1 in the 
transition state while associated with Dock1 and Rac1, and this stabilization is 
responsible for the increase in exchange activity seen with this trimeric complex [41]. 
ELMO proteins also play a role in proper localization of Dock-family proteins, by 
binding to activated RhoG, another Rho-family GTPase, which functions to bring 
Dock/ELMO complexes to the membrane [47-49,74].  The N-terminal region of ELMO1 
is necessary and sufficient for this interaction [47,48].  Disruption of the RhoG-ELMO1 
complex by mutation of the N-terminus of ELMO1 results in the failure of the 
Dock1/ELMO1 complex to promote phagocytosis, cell migration, formation of 
lamellipodia and the mutant complex is not localized to membrane ruffles [49]. 
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Defining the mechanism by which Dock and ELMO proteins function together 
would provide a greater understanding of how the various biological effects of the 
complex are carried-out and regulated.  Here we refine the predicted domain boundaries 
for Dock1, Dock2 and ELMO1, as well as identify new domains.  We show that isolated 
ELMO1 exists as a monomer, and can interact with both Rac1 and RhoG.  This 
interaction is nucleotide-dependent, and is dependent upon the presence of the polybasic 
region (PBR) of Rac1 and/or RhoG.   We demonstrate that Dock2 and ELMO1 can be 
purified as a stable complex, and this Dock2/ELMO1 complex exists as an obligate 
heterotetramer, consisting of two molecules each of Dock2 and ELMO1.  We also 
describe the substrate specificity of the complex using a screen of purified GTPases, and 
demonstrate that this tetramer binds a single molecule of Rac1.   
Experimental procedures 
Domain architecture prediction 
Domain analysis of Dock1, Dock2 and ELMO1 was carried out using a 
combination of sequence alignments using ClustalX version 1.83 [99], protein-protein 
BLAST and psi-BLAST searches [100], secondary structure prediction programs, and 
tertiary structure prediction and threading programs [100-106]. 
Plasmids 
ELMO1 constructs for insect cell expression were PCR-amplified and inserted 
into pFastBac1 using a modified ligation-independent cloning strategy (LIC) [107].  
ELMO1 (1-727) was amplified from pGEX4T2-ELMO1 [40]. 
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Full-length human Dock2 (1-1830) was PCR-amplified from pCXN2-Flag-
Dock2, a gift of Dr. Michiyuki Matsuda [32,33], and cloned into a modified pFastBac1 
vector (Invitrogen) using a LIC strategy [107].  The resulting construct encodes a non-
cleavable hexahistadine tag immediately preceding the N-terminus of Dock2.   
RhoG-pGEX4TEV2 and Rac1 constructs (C189S and Δ177) were as described 
[108,109].  HA-Rac1 (3X-HA epitope N-terminal to Rac1) was amplified from 
RAC010TN00 (UMR cDNA Resource Center), introducing a C189S mutation and stop 
codon, as well as NcoI and XhoI sites, and the fragment was ligated into pET15b via the 
NcoI and XhoI sites.  Flag-Rac1 was amplified from Rac1C189S introducing a Flag 
epitope at the N-terminus of Rac1, and was ligated into pET15b as above.  All new 
constructs were verified by automated sequencing. 
Protein purification 
Baculoviruses encoding the Dock2 and ELMO1 constructs were generated from 
the pFastBac vectors using the Bac-to-Bac system (Invitrogen).  High-Five insect cells 
were co-infected with viruses encoding Dock2 and ELMO1.  Cells were harvested by 
low-speed centrifugation after incubation at 27°C for 48 hours with shaking at 140 rpm.  
Cells were resuspended in 20 mM Tris, 1 M NaCl, 5 mM imidazole, 10% glycerol, pH 
8.0 (buffer N1).  Cells were lysed with an Emusiflex-C5 homogenizer (Avestin), and 
lysate was cleared by centrifugation at 265,000 x g for 45 minutes at 4°C.  Cleared lysate 
was passed through a 0.45 µm filter before being loaded onto a 5 ml nickel-charged metal 
chelating column (GE Healthcare) equilibrated with buffer N1.  The protein bound to the 
column was washed with buffer N1 and buffer N1 containing 50 mM imidazole before 
being eluted with buffer N1 containing 400 mM imidazole.  Fractions containing 
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Dock2/ELMO1 were pooled and concentrated to 10 ml in a 10K MWCO Vivaspin 
(Vivascience) 20 ml concentrator before being loaded onto a 26/60 Sephracryl S300 size 
exclusion column (GE Healthcare) equilibrated in 20 mM Tris, 300 mM NaCl, 10% 
glycerol, 2 mM DTT, pH 8.0.  Fractions containing Dock2/ELMO1 were pooled and 
dialyzed versus 20 mM Tris, 100 mM NaCl, 2 mM DTT, pH 8.0, concentrated as above, 
snap frozen in liquid N2, and stored at -80°C. 
Bacterially-produced ELMO1 and ELMO1ΔN were expressed as GST-fusion 
proteins from pGEX4T2-ELMO1 and pGEX4T2-ELMO1 532-727 in the BL21(DE3) E. 
coli strain.  Cells expressing ELMO1 were grown at 37°C in Terrific Broth (TB) until 
they reached an absorbance at 600 nm (A600) of ~0.8, then protein expression was 
induced with 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG).  Cells were allowed 
to grow ~12 hours at 25°C before harvesting by low-speed centrifugation. Cells 
expressing ELMO1ΔN were grown at 37°C in self-inducing ZYM-5052 media [110] 
until they reached an A600 of ~0.6, then cells were allowed to grow ~15 hours at 20°C 
before harvesting by low-speed centrifugation.  Cell pellets were resuspended in 20 mM 
Tris pH 8.0, 150 mM NaCl, 2 mM DTT, and 10% glycerol (GST buffer), lysed using an 
Emulsiflex-C5 homogenizer (Avestin), and clarified by ultracentrifugation at ~150,000 x 
g.  Clarified supernatant was loaded onto a 5 ml GSTrap FF column (GE Healthcare) pre-
equilibrated with GST buffer, and eluted with GST buffer supplemented with 10 mM 
reduced glutathione.  Fractions containing GST-ELMO1 or GST-ELMO1ΔN were 
pooled and the GST tag was cleaved overnight with thrombin.  ELMO1 was dialyzed into 
20 mM Tris pH 8.0, 10 mM NaCl, 2 mM DTT and 10% glycerol (buffer Q) and loaded 
onto an anion-exchange chromatography column pre-equilibrated with buffer Q, then 
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eluted with a linear gradient of 10-300 mM NaCl.  Fractions containing ELMO1 were 
pooled and dialyzed vs. GST buffer, and remaining fusion protein was removed using a 5 
ml GSTrap FF column.  ELMO1ΔN was dialyzed into 20 mM HEPES pH 7.0, 10 mM 
NaCl, 2 mM DTT and 10% glycerol (buffer S1) and loaded onto a cation-exchange 
chromatography column pre-equilibrated with buffer S1, then eluted with a linear 
gradient of 10-300 mM NaCl.  Fractions containing ELMO1ΔN were pooled and 
dialyzed vs. GST buffer, and remaining fusion protein was removed using a 5 ml GSTrap 
FF column.  ELMO1 and ELMO1ΔN were concentrated using 10K MWCO Vivaspin 20 
ml concentrators, snap frozen in liquid N2, and stored at -80°C. 
GST-ELMO2 was expressed from pGEX4T2 as for ELMO1, and purified 
essentially as described above for ELMO1 through the first affinity chromatography step.  
GST-ELMO2 was then concentrated, snap frozen and stored at -80°C. 
ELMO1 was also produced in insect cells.  The protein was expressed and 
purified as above for the Dock2/ELMO1 complex with a few changes.  Less virus 
encoding Dock2 relative to ELMO1 was used, and ELMO1 contained an N-terminal 
hexa-histidine tag.  A small amount of excess ELMO1 was purified away from the 
Dock2/ELMO1 complex during the size exclusion chromatography step and then stored 
at -80°C for subsequent analysis. 
The GST-RhoG expression construct was expressed in the BL21(DE3) E. coli 
strain.  Cells were grown at 37° in enriched media (24 g yeast extract and 12g tryptone 
per liter, pH 7.4) supplemented with 0.1 mg/ml ampicillin until they reached an A600 of 
~0.8, then protein expression was induced with 0.1 mM IPTG.  Cells were allowed to 
32 
 
grow ~15 hours at 20°C before harvesting by low-speed centrifugation.  RhoG was 
essentially purified as described [108]. 
Rac1 proteins (residues 1-189 C189S and Δ177) were expressed and purified 
essentially as described [108,109].  HA-Rac1 and Flag-Rac1 were purified as described 
for Rac1 C189S [108]. 
Size and oligomeric state determination 
ELMO1 purified from bacteria and from insect cells was subjected to size 
exclusion chromatography on a Superdex 200 10/300 GL (GE Healthcare) analytical 
column.  The molecular weight was estimated by comparing the peak elution volume to 
the peak elution volumes of a set of globular proteins of known molecular weight applied 
to the same column under similar conditions. 
Light scattering measurements were made with a Wyatt DAWN EOS light 
scattering instrument (Wyatt Optilab refractometer, and Wyatt dynamic light scattering 
module) interfaced to an AKTA FPLC (GE Healthcare).  100 µl of the Dock2/ELMO1 
complexes at 2 mg/ml were loaded onto a Superose 6 10/300 GL column (GE 
Healthcare) pre-equilibrated in 20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM DTT and 
0.02% NaN3 at 25°C.  For ELMO1 samples, 100 µl at 4.5 mg/ml was loaded onto a 
Superdex 200 10/300 GL column (GE Healthcare) pre-equilibrated with the same buffer 
as above.  Data collection and analysis was performed with ASTRA software version 
4.90.08 (Wyatt technologies).  The refractive increment (dn/dc) was set at 0.185 for each 
protein in the molecular mass calculations, based on the premise that dn/dc is constant for 
unmodified proteins [111].  Experiments were repeated 3-5 times. 
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Native PAGE assays 
GTPases were pre-loaded with the indicated nucleotide (or lack thereof) by 
incubating with EDTA at 2 times the concentration of MgCl2 in the protein buffer 
(usually 2 mM EDTA) and 10-fold molar excess of desired nucleotide for 30 minutes at 
room temperature.  Loading reactions were then stopped by addition of 2.5-fold excess of 
MgCl2 over the concentration of EDTA (usually 5 mM MgCl2), except in the case of the 
nucleotide-depleted forms, where buffer containing 2 mM EDTA and no MgCl2 was 
used. 
GTPases were incubated at indicated concentrations with ELMO1 for 15 minutes 
at room temperature, then were put on ice and loaded onto a 12.5% or 20% PhastGel (GE 
Healthcare) in combination with Native gel buffer strips (GE Healthcare), using a 6-well 
comb which loads 4µl of sample per well.  Gels were run with the manufacturer’s 
suggested protocols for 12.5% or 20% native gels.  Proteins were visualized by 
Coomassie brilliant blue staining. 
Surface plasmon resonance assays 
Utilizing a BIACORE 3000 surface plasmon resonance (SPR) instrument (GE 
Healthcare), anti-GST antibody was coupled to a CM5 chip per the manufacturer’s 
instructions (GE Healthcare).  Equal response units of indicated, GST-fusion ligand 
proteins were loaded onto the chip by brief injections of protein over the antibody 
surface.  Interactions of Rho GTPases at a concentration of 10 µM were analyzed using 
the KINJECT command.  Graphs of the response units are plotted with curves for the 
ligand protein of interest (ELMO1 or ELMO2) overlaid on the corresponding curve for 
the GST-only ligand surface to identify interactions. 
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Exchange assays – loading 
Exchange assays monitoring loading of GTPase with fluorescent nucleotide was 
carried out in 20 mM HEPES, 200 mM NaCl, 10 mM MgCl2, 1 mM DTT, 100 nM 
BODIPY-FL-GDP and 10% glycerol at 10°C.  GTPases were added to 2 µM and 100 nM 
Dock2/ELMO1 complex or 20 mM EDTA were added as exchange factors.  Loading of 
BODIPY-FL-GDP onto the GTPase was monitored by an increase in fluorescence by a 
Perkin-Elmer LS-55 fluorimeter with excitation and emission wavelengths of 503 and 
511, respectively.  Addition of EDTA was used to confirm the GTPase was active.  Rac 
and RhoG purifications are described above.  All other GTPases were purified as 
described [112]. 
Rac-binding immunoprecipitation 
Purified Dock2/ELMO1, Flag-Rac1, HA-Rac1 and Rac1Δ177 were added as 
indicated to appropriate reactions.  450 pmoles Dock2/ELMO1 was used per reaction, 
and 450 pmoles of the tagged Rac1 construct was used per reaction.  900 pmoles of 
Rac1Δ177 was used per reaction.  Proteins were diluted to equivalent concentrations in 
20 mM HEPES pH 7.5, 150 mM NaCl, 5 mM EDTA, and allowed to incubate with each 
other, as indicated, for 15-30 minutes at 25°C.  Anti-HA antibody-coupled beads (Roche) 
or Anti-Flag M2 antibody-coupled beads (Sigma) were washed with wash buffer (20 mM 
HEPES pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.25% NP-40, 100 µg/ml BSA) and 25 µl 
of appropriate beads were used per reaction.  Wash buffer was added to reactions to bring 
the volume up to 500 ml and the tubes were incubated at 4°C on a rotator for 90 minutes.  
Beads were collected by centrifugation at 6000 x g for 30 seconds, and supernatant was 
removed by aspiration.  Beads were washed 3 times with 1 ml wash buffer and protein 
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was eluted by boiling in 30 µl SDS-PAGE gel-loading dye.  Samples were loaded onto an 
SDS-PAGE gel, and bound proteins were visualized by staining with Coomassie brilliant 
blue. 
Results 
Dock1, Dock2 and ELMO1 domain architecture 
To determine if there are additional predicted domains within the sequences of 
Dock-family members and ELMO proteins, and to help define the domain boundaries of 
published, predicted domains, we used a combination of multiple sequence alignments, 
secondary structure prediction programs, tertiary structure prediction programs and 
threading algorithms.  Others have reported that ELMO1 contains a PH domain, a 
leucine-zipper motif, a PxxP motif, and Armadillo repeats.  We found, through our 
analysis, that the PH domain boundaries predicted by SMART are reasonable, if a bit 
extended, and thus, we labeled the PH domain as consisting of residues 555-677 (Fig. 
3B).  BLAST analysis of the PH domain of ELMO1 finds the PH domain of PLC-δ to 
have the highest homology with that region.  We did not find convincing evidence, 
however, for the predicted leucine zipper motif, and believe it to be unlikely to exist 
within the predicted PH domain of ELMO1, which is where a potential leucine zipper 
was identified [40].  The PxxP motif at the C-terminus is conserved amongst the different 
ELMO proteins (1, 2 and 3) and across species and is located within residues 707-717 of 
mouse ELMO1 (Fig. 3B).  Reportedly, ELMO1 contains Armadillo (ARM) repeats, 
which are regions of about 35-50 amino acids that form three alpha helices per repeat.  
Each repeat stacks with others, usually forming a superhelix of helices [113,114].  We 
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also found evidence for the ARM repeat region in the ELMO proteins; however, we 
would define the boundaries of the ARM repeat region differently than published.  The 
N-terminal region of mouse ELMO1 was repeatedly aligned with SCOP family a.118.1 
(ARM repeats [115]) when using a meta-server which compiles data from a variety of 
prediction and threading programs (http://www.bioinfo.pl/meta).  Upon examination of 
the models and alignments built by the threading algorithm, 3D-PSSM, and several 
secondary structure prediction programs, we determined that the most likely boundaries 
for the ARM repeat region span residues 81-515 (Fig. 3B). 
We performed a similar domain analysis for Dock1 and Dock2.  Previously-
predicted domains for Dock proteins were largely based on homology with other family 
members, since only a few domains had been predicted with a high degree of confidence.  
The SH3 domain of Dock1 and Dock2 is readily identified by programs such as SMART, 
and the boundaries are labeled accordingly.  The DHR-1 and DHR-2 regions have not 
been identified as structural domains, but as regions of homology as their names suggest 
(Dock-homology-region-1 or 2).  The limits of the DHR-1 region are labeled based on 
the literature (Dock1 422-664) [26,38], and the limits of the DHR-2 region are also based 
on the literature, but with refinements from our own multiple sequence alignments and 
secondary structure predictions (Dock2 1100-1617) [25,26,28].  The proline and serine-
rich region at the C-terminus of Dock1 is shown as identified from the sequence; Dock2 
does not have a noticeable proline/serine rich region (Fig. 3A) [33,35,53,116].   
To delineate other domains within the Dock protein sequences, we used portions 
of the sequences outside of defined domains to aid the prediction programs by 
eliminating easily-defined domains.  Within these sequences, domains were often 
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identified with low confidence scores, but the scores could be increased by using the 
boundaries defined by the initial hits to refine our sequence range.  A C2 domain was 
identified within the DHR-1 region using 3D-PSSM.  As the domain limits were refined 
by multiple rounds of 3D-PSSM and secondary structure predictions, the confidence 
score increased into the 95% confidence range (Fig. 3A).  This independently-predicted 
C2 domain was mentioned in earlier literature [26], but was more or less ignored until a 
later paper defining phosphoinositide-binding properties of the DHR-1 region re-
examined the region [38].  This paper defines the C2 domain as residues 422-587 of 
Dock1, but suggests that the minimum lipid-binding site encompasses residues 422-619.  
Our assessment of the domain would suggest an even smaller region for the actual C2 
domain, including residues 422-560 (Fig. 3A). 
A similar method was used to delineate the Armadillo repeat region of Dock1 and 
Dock2.  Similar to the ELMO1 ARM repeats, the results returned from a meta-server 
(http://www.bioinfo.pl/meta) identified the region from approximately residues 600-1340 
as belonging to the SCOP family a.118.1, or ARM repeats.  The region defined by 
homology to various ARM repeat proteins from the results compiled by the meta-server 
were submitted separately to 3D-PSSM and the resulting ARM repeat models were in the 
95% confidence range.  The ARM repeat region was defined by combining these results 
from the meta-server, the 3D PSSM results and several secondary structure predictions 
(615-1332, Dock1; 600-1339, Dock2; Fig 1A).  Interestingly, the ARM repeat region 
extends well into the DHR-2 region, but does not contain the entire DHR-2 region.  We 
were unable to detect any known domains within the latter half of the DHR-2 region, 
although there do seem to be secondary structure elements predicted, including both 
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helical and beta-sheet content, with random coil becoming much more prevalent 
immediately after the 1617 (Dock1) cutoff for the DHR-2 region.  In fact, once past the 
C-terminal end of the DHR-2 region, the remaining protein sequence is predicted to be 
primarily random coil. 
Despite the inability to predict any defined domains within the latter half of the 
DHR-2 region, COILS, a program which predicts coiled-coil (CC) regions within 
proteins [117], predicted a CC region spanning residues 1490-1510 in Dock1 and 1495-
1509 in Dock2.  This CC region was also predicted for Dock3, Dock4 and Dock5, and a 
mutation immediately preceding it (Dock1 ISP?AAA, residues 1487-1489) is known to 
eliminate the binding and exchange capacity of Dock1 [25].  The contribution of this 
predicted CC region to activity and/or dimerization has yet to be determined. 
Purified ELMO1 exists as a monomer 
ELMO1, purified from either insect cells or bacteria was examined by size 
exclusion chromatography (SEC) to determine the oligomeric state of the protein.  Since 
dimerization/oligomerization has been shown to be important both in a Dock1/ELMO 
complex and in Dock9 (zizimin1) [44,118], we wanted to determine if ELMO1 is self-
associating in order to better understand the oligomerization of the complex.  When 
analyzed over an analytical size exclusion column and compared to a range of proteins of 
known molecular weight run on the same column, we found that ELMO1 eluted at a 
volume consistent with a monomer of approximately 80 kDa (Fig. 4A).  Any dimers or 
higher-order oligomers of the protein would have been approximately 170 kDa and 
larger, and would have been clearly visible as a shifted peak elution volume on the SEC 
column used. 
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In addition to the SEC analysis, purified ELMO1 applied to an analytical SEC 
column was analyzed by multi-angle laser light scattering (Fig. 4B-C).  The protein 
eluted as a single, monodispersed peak with an average calculated molar mass of 87 kDa, 
with the standard deviation over three independent experiments being less than 1 kDa.  
This molecular weight is consistent with the approximate predicted value of an 84 kDa 
ELMO1 monomer.  These data show that purified ELMO1 exists solely as a monomer in 
solution.  This verifies that it is highly unlikely that any oligomerization of the 
Dock/ELMO complex originates with an ELMO-ELMO protein interaction. 
ELMO1 interaction with RhoG and Rac1 
Data from various papers detail an interaction between activated RhoG and the N-
terminus of ELMO1.  We examined this interaction using purified components to identify 
features of RhoG and ELMO proteins that are important to this interaction.  Native, or 
non-denaturing, polyacrylamide gel electrophoresis (Native PAGE) separates proteins 
based on size, shape, and isoelectric point (pI) of the protein(s) [119].  A gel-shift assay 
can be used to visualize protein-protein interactions, providing that a protein complex has 
properties (size, shape and/or pI) which are different enough from the individual proteins 
to visualize on a gel.   
We analyzed the ability of ELMO1 to form complexes with Rac1 and RhoG using 
native gels.  Neither Rac1 C189S or RhoG C188S were capable of entering the gel, 
presumably due to their high pI values as determined by ProtParam [101], which are 8.83 
and 8.46, respectively.  The RhoG/Rac1 and ELMO1 complex does not enter the gel 
either.  ELMO1, however, does enter the gel, and complex formation was monitored by 
depletion of the ELMO1 band in the gel caused by formation of the complex.  The 
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ELMO1 band was depleted, indicating complex formation, when ELMO1 was incubated 
with RhoG in its activated state, bound to GTPγS (a non-hydrolyzable GTP analogue). 
ELMO1 did not interact with RhoG in the GDP-bound or nucleotide-depleted form (Fig. 
5C).  Surprisingly, we also saw similar, nucleotide-specific interaction with Rac1-GTPγS 
(Fig. 5A).  We tested the ability of increasing amounts of RhoG-GTPγS and Rac1-GTPγS 
to deplete the ELMO1 band in the native gels, and found that, indeed, this was the case 
(Fig. 5B, D).  Interestingly, Rac1Δ177, which has the PBR removed, is incapable of 
forming a complex with ELMO1 (Fig. 3E). 
To further examine these interactions, we used surface plasmon resonance to 
measure binding of RhoG and Rac1 to ELMO1.  GST-ELMO1 or GST-ELMO2 and GST 
were used to create ligand protein surfaces on an anti-GST antibody-coupled CM5 chip.  
The binding of 10 µM Rac1 or RhoG was analyzed as relative response units (RU).  We 
compared the binding of each GTPase form to the GST surface, and found that both Rac1 
and RhoG bound to ELMO1 or ELMO2 only in the activated form (GTPγS-bound) and 
only when the PBR of the GTPase was present (binding is interpreted as an increase over 
the signal seen with GST).  Rac1Δ177, RhoGΔ177, Cdc42 and Ras were not capable of 
interacting with ELMO1, ELMO2 or GST in any nucleotide state (Fig. 6 and Fig. 7). 
These results show that the interaction of RhoG and Rac1 with ELMO1 and 
ELMO2 is specific, nucleotide-dependent and dependent upon the polybasic region.  The 
interaction of Rac1 with ELMO proteins was a surprise, considering that 
immunoprecipitation assays were able to detect the active RhoG-ELMO1 interaction, but 
not an interaction with active Rac1 and ELMO1.  Those assays were performed using the 
N-terminal 362 residues of ELMO1 [47], so perhaps the interaction with Rac1 is through 
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the C-terminal region of the protein.  Alternatively, these interactions with Rac1 could be 
an in vitro artifact due to the similarity of Rac1 and RhoG, which are 71% identical. 
Dock2 and ELMO1 are stably associated through the purification process 
Attempts to express and purify Dock2 in insect cells produced nearly no 
detectable protein, but when co-expressed when ELMO1, milligram quantities of purified 
complex were readily obtainable (Fig. 8B).  Critical components of the Dock2/ELMO1 
complex purification included protease inhibitors during lysis, clarification, and loading 
onto the affinity chromatography column.  Also important, 1 M NaCl increased apparent 
binding of the complex to the affinity column, as well as decreasing non-specific binding 
of other proteins.  Susceptibility to degradation necessitated a quick progression from 
lysis through the affinity and size exclusion chromatography (SEC) steps, all complete 
within 12 hours of lysis.  Once purified over the SEC column, continued degradation of 
the complex was negligible.  Some proteolytic fragments of Dock2 and ELMO1 typically 
purified with the complex and were removed by dialysis overnight into buffer containing 
50 – 100 mM NaCl which promoted specific precipitation of the fragments, which were 
subsequently removed by centrifugation.  After the addition of NaCl to 150 mM, the 
complex was concentrated and incubated at 37°C for 10 minutes to precipitate any further 
proteolytic fragments or unstable complex before being stored at -80°C.  Throughout the 
purification process, Dock2 and ELMO1 remained tightly associated, even in the 
presence of salt ranging from 0.05 – 1 M NaCl, with and without the presence of 
glycerol.  The purification yielded a highly-active complex of nearly homogeneous 
Dock2/ELMO1, stable at concentrations up to at least 40 mg/ml.  In addition, the 
Dock2/ELMO1 complex was able to form a trimeric complex with purified Rac1 upon 
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incubation of the two proteins in the presence of EDTA.  This trimeric complex was 
stable and excess Rac1 could be purified away by use of a SEC column (Fig. 8B). 
Dock2/ELMO1 is an efficient, specific exchange factor for Rac isoforms 
Dock2 is known to activate Rac1 and Rac2, and not Cdc42 or RhoA, but its 
activity on other GTPases has not been tested [26,53,54,56], nor has its efficiency as a 
GEF been evaluated.  To test the exchange specificity of the Dock2/ELMO1 complex, we 
performed fluorescence-based guanine nucleotide exchange assays on a library of 
GTPases.  Dock2/ELMO1 catalyzed exchange on Rac1, Rac2 and Rac3, as well as 
Rac1Δ177 (Fig. 8), but not on other Rho-family GTPases (Fig. 9), including RhoG, 
which is highly homologous to the Rac isoforms.  Dock2/ELMO1 was capable of 
exchange on Rac1 forms expressed with epitope tags (HA and Flag), but was completely 
inactive on an N-terminal GST fusion of Rac1 (data not shown).  Dock2/ELMO1 also 
failed to catalyze exchange on other GTPases belonging to the Ras superfamily (Fig. 10).  
When compared to Dbl-family GEFs in similar reaction conditions, the Dock2/ELMO1 
complex is an efficient exchange factor, comparable to, or even more efficient than, Dbl-
family GEFs that were tested (data not shown). 
Dock2/ELMO1 is a heterotetramer 
Several interactions between Dock and ELMO proteins have been defined, but the 
role that ELMO proteins play within the complex has been debated [27,94].  Zizimin1 
(Dock9) dimerizes via a portion of the DHR-2 domain, and Dock1 is capable of self-
association in an immunoprecipitation assay [118].  Endogenous Dock1 and ELMO 
proteins were also immunoprecipitated as a complex from HeLa cells, and the major 
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component proteins were identified using mass spectrometry as Dock1, ELMO2 and 
ELMO3.  The size of the complex was approximated at 700 kDa via size exclusion 
chromatography [44].  In order to better understand the functional relationship between 
Dock and ELMO proteins, we determined the stoichiometry of the complex using 
purified components. 
Dock2/ELMO1 applied to a size exclusion column eluted in a single, mono-
dispersed peak with a calculated molar mass of 598 ± 23 kDa (Fig. 11A) as determined 
by multi-angle laser light scattering [111].  This molecular mass is within the 
experimental error of the calculated weight (594 kDa; Fig. 11C) of a hetero-tetramer 
consisting of two molecules of Dock2 and two molecules of ELMO1; no other 
combination is consistent with the experimentally determined molecular weight.  Similar 
analysis of Dock2/ELMO1ΔN (Fig. 11B) yielded a molecular mass of 466 ± 7 kDa, 
which is very close to the predicted molecular mass (472 kDa) of a hetero-tetramer with 
2:2 stoichiometry (Fig. 11C).  Combined, these results strongly suggest that 
Dock2/ELMO1 exclusively exists as a stable 2:2 hetero-tetramer that does not require the 
N-terminal portion of ELMO1.  Hetero-tetramer formation is most likely mediated 
through Dock2, since zizimin1, which does not interact with ELMO1, is also dimeric 
[118].  In addition, it seems unlikely that ELMO1 contributes significantly to the 
dimerization interface, since size exclusion chromatography and light scattering analyses 
indicate that isolated ELMO1 is a monomer (Fig. 4). 
The Dock2/ELMO1 complex binds a single molecule of Rac 
The existence of Dock2/ELMO1 exclusively as a stable heterotetramer implies a 
functional significance to this particular oligomer.  To explore this possibility, we 
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examined the interaction between the Dock2/ELMO1 heterotetramer and Rac1.  A stable 
complex between Dock2/ELMO1 and nucleotide-depleted Rac1 can be made by 
incubating the purified proteins in the presence of EDTA and this Dock2/ELMO1/Rac1 
complex can be purified over a size exclusion column (Fig. 8B).  It is important to note 
that Dock2/ELMO1 is capable of binding to, and is fully active upon all forms of Rac1 
used in these assays (data not shown).  To determine the number of Rac1 molecules that 
bind to each tetramer of Dock2/ELMO1, we performed an immunoprecipitation assay 
utilizing differentially-tagged forms of Rac1.  Using purified proteins, we incubated 
Dock2/ELMO1 complex with either Flag-Rac1 or HA-Rac1 and non-tagged Rac1Δ177 
and performed an immunoprecipitation with anti-Flag or anti-HA beads as appropriate.  
The beads and bound protein were washed extensively, and then the bound proteins were 
eluted by boiling in SDS-PAGE gel-loading buffer, and were run on an SDS-PAGE gel.  
If two or more molecules of Rac1 were capable of interacting with the Dock2/ELMO1 
complex, both species of Rac1 would be visible on the gel.  If only one molecule of Rac1 
was bound to the Dock2/ELMO1 complex, then only the tagged form of Rac1 would be 
visible on the gel, as the Dock2/ELMO1 bound to the untagged-Rac1Δ177 would not be 
immunoprecipitated.  Surprisingly, we found that only a single molecule of Rac1 
associates with the Dock2/ELMO1 heterotetramer (Fig. 12).  This result suggests that 
either the structural layout of the tetramer is such that only one Dock2 molecule is 
capable of interacting with Rac1 or that the two Dock2 molecules cooperate to form the 
Rac1 binding site. 
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Discussion 
A significant body of literature describes the association of Dock and ELMO 
proteins, as well as the interaction between RhoG and ELMO1 (reviewed in Cote and 
Vuori [27]; Lu and Ravichandran [94]; and Meller, Merlot and Guda [29]).  The majority 
of these studies have been limited to using non-purified protein components in which it 
can often be difficult to distinguish direct effects of the proteins studied from the 
contributions of endogenous proteins.  We were able to use purified proteins to study the 
interactions between ELMO1 and RhoG, as well as the interactions and activity of the 
Dock2/ELMO1 complex. 
In native gel shift assays and surface plasmon resonance analysis, activated RhoG 
bound to ELMO1 in a manner consistent with previous reports [47,48,74].  Activated 
Rac1 was able to bind similarly, which is an interaction that has not been detected 
previously.  In fact the interaction between Rac1 and ELMO1 has been tested by pull-
down assays [47] and yeast two-hybrid assays [40] and no binding was detected.  Not 
only did these two Rho-family GTPases bind to ELMO1 in a GTP-dependent manner, 
this association also required the polybasic region (PBR) of the GTPase.  Binding 
dependent upon the PBR is reported for other ARM repeat containing proteins, such as 
SmgGDS, a non-Dbl-family GEF specific for RhoA and RhoB [4,18].  Additionally, 
FHOS, a member of the formin family of proteins, is known to require the PBR to bind to 
Rac1 [120].  Formins use ARM repeats, in addition to a helical GTPase binding domain, 
to bind Rho-family GTPases, although in the crystal structure of mDia bound to RhoC a 
truncated form of RhoC missing the PBR was used [121,122]. 
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The significance of activated Rac1 binding to ELMO1 is yet to be determined.  It 
is possible that Rac1, being 71% identical to RhoG, is simply mimicking, in vitro, the 
biologically-relevant association of activated RhoG with the N-terminus of ELMO1.  The 
potential for this binding of Rac1 to ELMO1 to be a bona fide interaction must also be 
considered.  This could indicate the presence of a feed-forward loop, whereby a 
Dock/ELMO complex activates Rac1, which goes on to bind to ELMO1, and perhaps, 
increase or help sustain the exchange activity of the Dock/ELMO complex.  Interactions 
similar to this have been reported for the Ras GEF Son of sevenless (Sos) and for the 
Cdc42-specific Dock11, where the activated substrate GTPases of the GEFs return to 
bind the exchange factor.  In the case of Sos, activated Ras binds through the PH domain 
[123,124], and activated Cdc42 binds through the N-terminus in the case of Dock11 [88].  
Future analyses of the binding between Rac1 and ELMO1 using truncation mutants of 
ELMO1 will be useful in determining the biological relevance of this interaction. 
Although detailed data on the interactions between Dock-family proteins and 
ELMO proteins are available, Dock-family proteins are often treated as separate entities.  
Our results provide evidence that the Dock/ELMO complex is a stable heterotetramer that 
acts as an exchange factor upon Rac isoforms in a Dock:ELMO:Rac stoichiometry of 
2:2:1.  These data would support a hypothesis that Dock-family proteins in the Dock A 
and Dock B subfamilies exist as obligate heterotetramers with ELMO proteins. 
One indication of the obligatory nature of the interaction between Dock2 and 
ELMO1 was the necessity of co-expressing both of these proteins in insect cells in order 
to purify any detectable protein.  In fact, once the two proteins were co-expressed, the 
quantities of proteins able to be purified per liter of cell culture changed from essentially 
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zero to several milligrams of pure protein.  When expressed alone, Dock2 was produced 
since an elution fraction from the initial affinity column did possess exchange activity 
towards Rac1.  The protein, however, was not clearly visible on a gel and the elution 
fraction contained a large number of contaminating peptides, as determined by SDS-
PAGE.  The possibility that ELMO1 protects Dock2 from degradation within the insect 
cells is supported by a paper from Makino et al. [45], which shows that ELMO1 inhibits 
ubiquitylation of Dock1. 
Extending beyond the idea of protection from proteolysis, we found that the 
Dock2/ELMO1 complex is very stable, even in conditions ranging from 50 mM to 1M 
NaCl, and incubation at 37°C.  The complex stayed tightly associated through the entire 
purification process.  The stability of the complex was emphasized by the light scattering 
experiments in which the single elution peak for the complex was found to be nearly 99% 
monodispersed.  This indicates that the entire peak which eluted from the size exclusion 
column contained a single species.  The lack of any sort of detectable dissociation by this 
complex supports a hypothesis that the interaction between the ELMO proteins and the 
Dock-family proteins (Dock A and Dock B families) is an obligatory interaction. 
We also showed that the heterotetramer consisting of 2 molecules each of Dock2 
and ELMO1 is a fully active, specific GTPase for Rac1, Rac2 and Rac3, but no other Rho 
family or Ras superfamily members that were tested.  The heterotetramer functions as a 
single unit; only binding to one molecule of Rac1.  This is in contrast to published results 
for Dock9 (Zizimin1), in which the Dock9 dimer is shown to bind a single molecule of 
Cdc42 [118].  It is unlikely that the two Dock-family proteins, although only distantly 
related within the family, interact with their respective substrate proteins in such a 
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different manner.  To resolve this difference, we would propose that the data in Meller, et 
al. could be interpreted differently.   
A non-Cdc42-binding mutant utilized in the paper showed a decrease in 
dimerization capability.  The authors reported decreased binding to Cdc42 for a dimer of 
this mutant and wild-type Dock9 and interpreted Cdc42 binding to this mutant/wild-type 
dimer as evidence for one Cdc42 binding site per Dock9 molecule.  We hypothesize, 
rather, that the impaired dimerization capability of the mutant results in a reduced binding 
affinity for a single molecule of Cdc42.  If each Dock-family protein provides a part of 
the binding site for the GTPase, then a fault in dimerization could damage the ability of 
that molecule to bind the GTPase.  Meller, et al. also reported that a small fragment of 
Dock9 with poor dimerization capabilities was sufficient to bind Cdc42, and suggested 
that this supported the stoichiometry of one Cdc42 molecule per Dock9 molecule.  While 
a reasonable conclusion, we would argue that, in light of this new data with purified 
proteins, each of the two Dock-family proteins in the dimer/heterotetramer may provide 
part of the GTPase binding site.  A construct of the Dock protein containing the binding 
site, but with sub-optimal dimerization may still interact with the substrate GTPase, but 
poorly.  In support of this idea, we have noted a coiled-coiled region predicted within the 
DHR-2 region of Dock1 through Dock5 (Fig 1A).  A mutation which abolishes Dock1 
exchange activity (Dock1 ISP) is located immediately N-terminal to this region [25].  
Examining the dimerization capabilities of this known GEF-dead mutant may provide 
additional evidence for this hypothesis.
 Figure 3: Schematic representation of Dock1, Dock2 and ELMO1 constructs and domains. 
A) Predicted domain structure of human Dock1 (Dock180) and Dock2.  Numbers denote amino acid 
residues for the boundaries of predicted regions.  SH3 domain in yellow, C2 domain in cyan, region 
containing armadillo (ARM) repeats in red, coiled-coil region in blue, proline and serine-rich region (P/S 
rich) in white.  Docker-homology region-1 (DHR-1) and docker-homology region-2 (DHR-2, or Docker 
domain) are represented by black bars.  B) Predicted domain structure, constructs and mutants for mouse 
ELMO1.  Region containing predicted ARM repeats in red, PH domain in green and PxxP motif in 
magenta.  Numbers denote residues for beginning and end of constructs and of domains.  Point mutations 
are labeled on the ELMO1GL construct. 
 
 
 
 
 
 
 
 
50 
 
 Figure 4: Purified ELMO1 is a monomer in solution. 
A) ELMO1 purified from bacteria (red) and insect cells (blue) was applied to an analytical SEC column.  
The resulting chromatograms are overlaid.  The peak elution volume was compared to the elution volumes 
of globular proteins of known size applied to the same column, and a molecular weight of ~83 kDa was 
calculated for both ELMO1 protein samples.  B) ELMO1 was subjected to SEC-coupled multi-angle laser 
light scattering to determine molecular weight and eluted in a single peak with a calculated molecular 
weight of 87±1 kDa.  C) Experimentally determined molar mass of ELMO1 plotted vs. elution volume of 
the light scattering peak.  The nearly horizontal molar mass data indicates monodispersity of the sample. 
51 
 
 Figure 5: Binding of Rac1 and RhoG to ELMO1 is both nucleotide-dependent and PBR-dependent. 
ELMO1 and RhoG/Rac1 complex formation was monitored by depletion of the unbound ELMO1 band in 
non-denaturing polyacrylamide (native) gels, using an elctrophoretic mobility shift assay (gel shift).  
Proteins were detected by Coomassie brilliant blue staining.  A) ELMO1 (50 µM) was incubated with Rac1 
(100 µM) in a GDP-bound, GTPγS-bound or nucleotide-free (EDTA) state.  B) ELMO1 (50 µM) was 
incubated with increasing concentrations of Rac1-GTPγS.  C) ELMO1 (25 µM) was incubated with RhoG 
(100 µM) in a GDP-bound, GTPγS-bound or nucleotide-free (EDTA) state.  D) ELMO1 (25 µM) was 
incubated with increasing concentrations of Rac1-GTPγS.  E) ELMO1 (50 µM) was incubated with 
Rac1Δ177 (100 µM) in a GDP-bound, GTPγS-bound or nucleotide-free (EDTA) state. 
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Figure 6: ELMO1 binding to RhoG and Rac1 is nucleotide and PBR dependent. 
A-C) Ligand surfaces of GST-ELMO1 or GST were coupled to a CM5 chip modified with covalently-
bound anti-GST antibody.  Binding of 10 µM GTPases, either GDP- or GTPγS-bound was monitored by 
the increase in response units (RU) via surface plasmon resonance.  Binding to ELMO1 (red) is measured 
as an increase in RU over that of the GST control (blue). 
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 Figure 7: ELMO2 binding to RhoG and Rac1 is nucleotide and PBR dependent. 
A-C) Ligand surfaces of GST-ELMO2 or GST were coupled to a CM5 chip modified with covalently-
bound anti-GST antibody.  Binding of 10 µM GTPases, either GDP- or GTPγS-bound was monitored by 
the increase in response units (RU) via surface plasmon resonance.  Binding to ELMO2 (red) is measured 
as an increase in RU over that of the GST control (blue). 
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 Figure 8: Dock2/ELMO1 is an effective GEF for Rac1, Rac1Δ177, Rac2 and Rac3. 
A) Rho-family GTPase tree.  Green indicates Dock2/ELMO1 is an effective exchange factor for GTPase.  
Red indicates lack of exchange activity by Dock2/ELMO1.  B) Purified Dock2/ELMO1 bound to Rac1.  C) 
Fluorescence-based exchange assays monitoring the loading of BODIPY-GDP onto GTPases (2 µM).  
Dock2/ELMO1 was used at 100 nM and EDTA was used at 20 mM as a control for GTPase activity. 
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 Figure 9: Dock2/ELMO1 does not catalyze exchange on other Rho-family GTPase members. 
Fluorescence-based exchange assays monitoring the loading of BODIPY-GDP onto GTPases (2 µM).  
Dock2/ELMO1 was used at 100 nM and EDTA was used at 20 mM as a control for GTPase activity. 
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 Figure 10: Dock2/ELMO1 does not catalyze exchange on other Ras superfamily GTPase members. 
Fluorescence-based exchange assays monitoring the loading of BODIPY-GDP onto GTPases (2 µM).  
Dock2/ELMO1 was used at 100 nM and EDTA was used at 20 mM as a control for GTPase activity. 
 
 
 
 
 
57 
 
 
Figure 11: Dock2/ELMO1 is a heterotetramer. 
A, B) Dock2/ELMO1 and Dock2/ELMO1ΔN samples were subjected to SEC-coupled multi-angle laser 
light scattering to determine molecular weight.  Both complexes eluted as a single, monodispersed peak.  
Upper panels: An overlay of the light scattering signal (red) and refractive index (blue) of each sample.  
The areas of peaks used for molecular weight determination are bounded by black lines.  The peaks at 7.5 
ml contained no detectable protein, and the peaks around 21.5 ml are due to sample buffer components.  
Lower panels: The molar mass of the selected peak is plotted vs. the elution volume of the peak.  The 
horizontal nature of the lines indicating molar mass indicates the samples are monodispersed.  The 
calculated molar mass is in cyan, the fit of the data to a parabola is in black, and the light scattering signal 
is in red.  C)  Table showing the predicted and experimentally determined molecular weights (MW) for the 
Dock2/ELMO1 complexes tested. 
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 Figure 12: The Dock2/ELMO1 tetramer binds a single Rac1 molecule. 
A) Dock2/ELMO1 and bacterially purified Flag-Rac1 and untagged Rac1Δ177, as indicated, were pre-
incubated, then precipitated by anti-Flag antibody-coupled beads.  Bound proteins were eluted by boiling in 
SDS-PAGE sample loading buffer and run on an SDS-PAGE gel, stained with Coomassie brilliant blue.  
Right panel shows purified proteins used.  B) Experiment was run as in (A), but with HA-tagged Rac1 
replacing Flag-Rac1, and anti-HA antibody-coupled beads were used for the immunoprecipitation. 
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CHAPTER 3 – RHOG DIRECTLY REGULATES THE ACTIVITY OF THE 
DOCK/ELMO COMPLEX VIA INTERACTION WITH ELMO PROTEINS 
Background 
The specific, functional role that ELMO proteins play within the context of the 
Dock/ELMO heterotetramer remains to be defined.  Although ELMO1 possesses no 
independent GEF activity, the PH domain of ELMO1 can interact in trans with a 
complex of Dock1 and nucleotide-free Rac1 independent of other defined Dock/ELMO 
interactions.  This interaction increases the exchange activity of Dock1 by about two-fold 
in vitro.  Interestingly, mutation of a tryptophan residue to alanine in the PH domain of 
ELMO1 can disrupt formation of this trimeric complex, and ELMO1 constructs 
containing this mutated PH domain are unable to synergize with Dock1 in exchange 
assays, although the proteins are still capable of interacting through the other defined 
interactions between Dock1 and ELMO1 [41].  Beyond the PH domain interaction and 
ELMO1 synergizing with Dock1 to enhance exchange activity [25,71], Makino, et al. 
describe the ability of ELMO1 to inhibit ubiquitylation of Dock1.  Potential evidence for 
this functionality was seen in our own results (Chapter 2), when we were only able to 
purify significant quantities of Dock2 from insect cells when it was co-expressed with 
ELMO1. 
In addition to whatever direct effects ELMO proteins have on the function of the 
Dock/ELMO tetramer, RhoG, a member of the Rho-family of GTPases interacts with the 
N-terminus of ELMO1 in its active, GTP-bound form.  Through this interaction, RhoG is 
able to translocate the primarily cytoplasmic Dock/ELMO complex to the plasma 
membrane [47,74].  RhoG activates Rac1 via the Dock/ELMO complex, and this 
pathway is required for integrin-mediated Rac1 activation and cell spreading, promotion 
of cell migration, as well as nerve growth factor-induced neurite outgrowth [47,48].  The 
Dock/ELMO complex is not, however, required for the RhoG-induced suppression of 
anoikis [125].  The activation of Rac1 by RhoG is usually attributed to the translocation 
of the Dock/ELMO complex to the plasma membrane. 
Here, we present data showing that there is an inhibitory intramolecular 
interaction between the N- and C-terminal regions of ELMO1.  Truncation of the N-
terminus of ELMO1 to relieve this interaction results in increased phagocytosis in LR73 
cells, as well as increased exchange activity of the Dock/ELMO complex.  Activated 
RhoG can approximate the effect of truncation by increasing the exchange activity of the 
Dock1/ELMO1 or Dock2/ELMO1 complex.  This activation is lost if the form of ELMO 
protein used is incapable of binding to RhoG.  The Dock2/ELMO1ΔN complex is also 
capable of increased binding to PI(3,4,5)P3 over that of the Dock2/ELMO1 wild-type 
complex.  We propose a model whereby activated RhoG binds the N-terminus of ELMO1 
to disrupt the inhibitory intramolecular interaction, thereby causing a conformational 
change which directly increases the exchange activity of the Dock2/ELMO1 complex. 
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Experimental Procedures 
Plasmids 
pEBB-ELMO1-GFP, ELMO1ΔN-Flag, ELMO1ΔC-Flag, ELMO1GL-Flag 
(previously ELMO1arm2-Flag) have been previously described [40,49]  To generate the 
pGBT10-ELMO1 vector, the Flag-ELMO1 coding sequence was removed from the 
pEBB-ELMO1-Flag vector with BamHI and NotI.  The insert was ligated into the 
BamHI–NotI site of a modified pGBT10 vector containing an AscI and NotI linker 
inserted between the BamHI and EcoRI sites with these two restriction sites intact. 
ELMO1 constructs for insect cell expression were PCR-amplified and inserted 
into pFastBac1 using a modified ligation-independent cloning strategy (LIC) [107].  
ELMO1 (1-727) and ELMO1ΔN (532-727) were amplified from pGEX4T2-ELMO1 
[40], with an N-terminal methionine added to initiate translation for ELMO1ΔN.  
ELMO1GL was amplified from pGEX4T2-ELMO1arm2 [49]. 
The pCXN2-Flag-Dock180 construct was from Dr. Michiyuki Matsuda [32,33].  
A construct encoding a GST fusion of the PH domain of mouse Grp1 in pGEX2TK (GE 
Healthcare) was a gift from Dr. Mark Lemmon [126].  Other plasmids were as described 
in Chapter 2, experimental procedures.  All new constructs were verified by automated 
sequencing. 
Protein purification 
GST-Grp1-PH was expressed as described [126].  The cells were harvested by 
centrifugation and lysed in 20 mM Tris pH 7.5, 1 M NaCl, 1% Triton X-100, 2 mM DTT, 
0.5 mM PMSF, and 1 tablet protease inhibitor cocktail (Roche) per 25 ml buffer, using an 
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Emulsiflex-C5 homogenizer (Avestin), and clarified by ultracentrifugation at ~150,000 x 
g.  Clarified supernatant was loaded onto a 5 ml GSTrap FF column (GE Healthcare) pre-
equilibrated with GST-PH buffer (20 mM Tris pH 7.5, 0.5 M NaCl, 0.1% Triton X-100, 2 
mM DTT, 0.5 mM PMSF, 10% glycerol, and 1 tablet protease inhibitor cocktail per ~100 
ml), and eluted with GST-PH buffer supplemented with 10 mM reduced glutathione.  
Fractions containing GST-Grp1-PH were pooled, concentrated using a 10K MWCO 
Vivaspin 20 ml concentrator, snap frozen in liquid N2, and stored at -80°C. 
Cell culture 
Mammalian cells were maintained in a moisturized incubator with 5% CO2 at 37º 
C.  Human 293T fibroblast cells were maintained in Dulbecco’s Modification of Eagle’s 
Medium containing 10% FBS and 1% penicillin/streptomycin/glutamine.  The Chinese 
Hamster Ovary fibroblast cell line LR73 [127] was maintained in Alpha’s Modified 
Eagle’s Medium supplemented with 10% FCS and 1% penicillin/streptomycin/glutamine.  
293T cells were transiently transfected by the calcium phosphate method and LR73 cells 
were transiently transfected using Lipofectamine 2000 (GIBCO-BRL) according to the 
manufacturer’s instructions [40].  In all experiments, carrier DNA was added to keep 
equal plasmid concentration between different samples. 
Immunoprecipitation assays 
Before lysis, all mammalian cells were washed with ice cold PBS.  Cells were 
then lysed on ice 48 hours after transfection for 10 minutes in lysis buffer containing 50 
mM Tris, pH 7.6, 1% (v/v) Triton X-100, 150 mM NaCl, 10 mM Sodium Pyrophosphate, 
10 mM Sodium Fluoride, 1 mM orthovanadate, 10 μg/ml AESF, 1 mM DTT, 10 μg/ml 
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Pepstatin, 10 μg/ml Aprotinin and 10 μg/ml Leupeptin.  Lysates were then cleared in a 
centrifuge for 10 minutes at 4˚C.  All beads were washed in lysis buffer prior to 
incubation with cell lysates or bacterially produced purified protein.  
Immunoprecipitations were performed as described previously [25,40].  Briefly, for 
precipitation of Flag tagged proteins, 20 μl of anti-Flag M2 antibody (Sigma) directly 
coupled to Sepharose was used per lysate from a 100 mm culture dish.  Cleared cell 
lysates were then incubated with the beads for 1-2 hours at 4º C on a Nutator.  Beads 
were then washed four times with 1 ml of washing buffer (20 mM Hepes, pH 7.4, 0.1% 
(v/v) Triton X-100, 150 mM NaCl, 5 mM Sodium Fluoride, 1 mM Orthovanadate, 10% 
(v/v) Glycerol, 1mM DTT, 10 μg/ml Pepstatin, 10 μg/ml Aprotinin, 10 μg/ml Leupeptin). 
Precipitated proteins were assessed by SDS-PAGE and immunoblotting.  Antibodies used 
as indicated were mouse monoclonal anti-GFP (clone B2, used at 0.5 μg/ml, Santa Cruz 
Biotechnology), Anti-Flag M2 monoclonal antibody (clone M2, used at 1:10,000, Sigma) 
and purified rabbit polyclonal anti-ELMO1 [25].  HRP-conjugated anti-rabbit and 
anti-mouse secondary antibodies (both used at 1:10,000) were from GE Healthcare.  
Immunoblots were developed using enhanced chemiluminescence (Pierce). 
Yeast two-hybrid assays 
The strain HF7C was employed and growth was monitored on -histidine, -
tryptophan, and -leucine selection media.  Briefly, constructs cloned into pGBT10 are 
fused to a DNA binding domain and transformants thrive on tryptophan selection media.  
Genes cloned into pVP16 are fused to an activation transformants will grow on media 
lacking leucine.  Yeast transformants carrying both plasmids will be able to grow on 
tryptophan and leucine deficient media. When the proteins of interest interact, those 
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transformants will also thrive in/on histidine-deficient media.  3-amino-1,2,4-triazole (3-
AT) inhibits histidine synthesis, and can be added to media to increase selectivity.  Cells 
were transformed using the Lithium Acetate-based transformation protocol.  Genes of 
interest were cloned into the pVP16 or the pGBT10 vectors as indicated. 
Exchange assays 
The radioactivity based in vitro GEF assay was performed as described previously 
[25] with minor modifications.  293T cells in 100 mm dish were transfected with either 
Flag-Dock1 or a Flag-ELMO1 construct + Dock1 and the cell lysates were 
immunoprecipitated with anti-Flag antibody.  Precipitated proteins were then eluted into 
120 μl with Flag peptide (Sigma) following manufacturer’s recommendation.  The eluted 
proteins were quantitated after Western blotting.  Equal amounts of Dock1 were analyzed 
for GEF activity toward Rac as follows: 5 μg of bacterially expressed and purified Rac 
was loaded with 50 μCi of [α-32P] GTP (3000 Ci/mmol) in 40 mM MOPS (pH7.1), 1 
mM EDTA, 1 mg/ml BSA and 0.3 μM unlabeled GTP, for 20 minutes on ice.  MgCl2 
was then added to 10 mM and incubated on ice for an additional 10 minutes.  125 ng 32P-
GTP loaded Rac was added with 10 μl of eluted proteins (for wild-type Dock1, volume 
for other samples was adjusted based on the concentration of eluted Dock1) to reaction 
buffer of 25 mM MOPS, pH7.1, 6.25 mM   MgCl2, 0.6mM NaH2PO4, 0.5 mg/ml BSA, 
1.25 mM GDP (unlabeled) to a final volume of 100 μl.  After 15 minutes at 30° C, 50 μl 
of the exchange reaction was subjected to filter binding to nitrocellulose and quantitated 
by scintillation counting.  The presence of GEF-activity was revealed as loss of 
radioactivity bound to Rac (i.e. due to the exchange reaction).  Relative GEF activity was 
presented as the percentage of radioactivity loss, with samples from mock-transfected 
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293T cell set at 0% and samples from wild-type Dock180 alone transfected cells at 
100%. Results are representative of at least five independent experiments. 
Fluorescence-based exchange assays utilized either Rac1(C189S) or Rac1Δ177 
pre-loaded with BODIPY-FL-GDP.  To load the GTPase, Rac1 was incubated for 30 
minutes at room temperature with 2-5 mM EDTA, and ~3-fold molar excess of BODIPY-
FL-GDP.  After incubation, 10-20 mM MgCl2 was added and the excess nucleotide was 
removed using a Hi-Prep desalting column (GE Healthcare) pre-equilibrated with 20 mM 
HEPES pH 7.5, 150 mM NaCl, 2 mM DTT, 10 mM MgCl2 and 10% glycerol.  Aliquots 
were snap frozen in liquid N2, and stored at -80°C.  RhoG was loaded with GDP and 
GTPγS in a similar manner, with the exceptions that a 10-fold molar excess of GDP or 
GTPγS was used.  Efficient nucleotide loading for RhoG was confirmed using a 
radioactive filter binding assay and GTPγ35S.  When used in exchange reactions, RhoG 
was pre-incubated with the indicated GEF for a minimum of 15 minutes at 25°C. 
Exchange assays utilizing Rac1 pre-loaded with BODIPY-FL-GDP were carried 
out in 20 mM HEPES, 200 mM NaCl, 10 mM MgCl2, 1 mM DTT, 100 µM GDP and 
10% glycerol at 10°C on a Perkin-Elmer LS-55 fluorimeter, using excitation and 
emission wavelengths of 503 and 511 nm.  Rac1 was used at 150 nM, Dock2/ELMO1 
complexes were added to 15 nM and RhoG was used at 10 µM.  Data analysis was 
carried out in GraphPad Prism software version 4.0. 
Flag-Dock1 and Dock1/Flag-ELMO1 complexes were obtained by 
immunoprecipitation as described for the radioactive GEF assays.    Equal amounts of 
Dock180 were analyzed for GEF activity using 150 nM Rac1-BODIPY-FL-GDP as 
above. 
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Phosphoinositide binding assays 
PIP-beads precipitation - Purified Dock2/ELMO1 and Dock2/ELMO1ΔN were 
incubated with PI(3,4,5)P3 beads (Echelon Biosciences) in varying amounts (5, 25, 50 
and 250 pmoles of tetramer per reaction) in buffer containing 20 mM HEPES, pH 7.5, 
150 mM NaCl, 0.25% NP-40 and 0.5 mg/ml BSA for 3 hours on a rotator at 4°C, in a 500 
µl total volume.  20 µl of bead slurry (washed with buffer) was used per condition.  After 
incubation, beads were collected by centrifugation at 1000 rpm for 3 minutes and the 
supernatant was aspirated away from the beads.  The beads were washed with 1 ml 
buffer, spun, and the supernatant removed 3 times.  Bound proteins were eluted by 
boiling in 20 µl 2X SDS-PAGE loading dye, and samples were run on SDS-PAGE gels.  
Dock2/ELMO1 complex binding was measured by the N-terminal 6X-His tag on Dock2 
via western blotting by incubating with Penta-His HRP conjugate (Qiagen) antibody, and 
was detected with enhanced chemiluminescence (ECL, GE Healthcare).  To test for 
specificity, PIP beads conjugated to PI, PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, PI(3,5)P2 and 
PI(3,4,5)P3 were utilized in assays as above, with 25 nM pmoles of tetramer per assay. 
Fluorescence polarization - ELMO1, ELMO1ΔN or GST-Grp1-PH were titrated 
into buffer (20 mM HEPES pH 7.5, 200 mM NaCl, 1 mM DTT) containing 50 nM 
PI(3,4,5)P3 labeled with BODIPY-FL (Echelon Biosciences).  Titrations were performed 
manually at 25°C, and the change in polarization was measured in triplicate for each 
concentration assayed [128].  Data were fit to a single-site binding model using non-
linear regression with SigmaPlot software to yield parameters for Pmin (starting 
polarization), Pmax (maximum polarization), and KD (dissociation constant). 
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Results 
Intramolecular interaction within ELMO1 
In Chapter 2, size exclusion chromatography and light scattering data show that 
purified ELMO1 exists as a monomer in solution (Fig. 4).  In contrast, 
immunoprecipitations suggest that full-length Flag-ELMO1 is capable of interacting with 
full-length GFP ELMO1 when co-transfected into human 293T fibroblasts (Fig. 13).  To 
resolve this conflict, we examined whether the interactions we were seeing in the 
immuoprecipitations were actually stemming from intramolecular interactions within 
ELMO1, rather than intermolecular interactions between different ELMO1 molecules.   
To test this, we examined the capability of different pieces of ELMO1 (Fig. 13) to 
interact via immunoprecipitation assays.  Full-length Flag-ELMO1 was capable of 
precipitating full-length GFP-ELMO1, as well as ELMO1ΔN, ELMO1ΔC and 
ELMO1GL, a mutant incapable of interaction with active RhoG.  Flag-ELMO1ΔC, 
encompassing residues 1-550, precipitated full-length ELMO1, but not ELMO1ΔN, 
while ELMO1ΔN, encompassing residues 532-727, precipitated both full-length ELMO1, 
and ELMO1ΔC.  It is unclear why ELMO1ΔC failed to precipitate ELMO1ΔN, when the 
precipitation worked in the reverse direction, but this is likely caused by interference due 
to the nature of antibody binding to the tagged ELMO1 fragments.  These 
immunoprecipitations suggest that there is an interaction within or between ELMO1 
molecules that involves both the N- and C-terminal portions of ELMO1 
Yeast-two hybrid assays were employed to further examine these interactions. 
Plasmid constructs encoding ELMO1, ELMO1ΔN and ELMO1ΔC in the appropriate 
fusions with the DNA binding domain or activation domain were co-transformed in 
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various combinations in yeast and growth of the transformants were monitored on 
selective media (Fig. 14A).  Of the combinations tested, the interaction between 
ELMO1ΔC and ELMO1ΔN was the strongest, showing yeast growth comparable to that 
of the known interaction between ELMO1ΔC and constitutively active RhoG (Q61L).  
These data, combined, suggest that the detected ELMO1-ELMO1 interactions originate 
from an intramolecular interaction between the N- and C-terminal portions of ELMO1. 
To test the existence of an intramolecular association between the N- and C-
terminal portions of ELMO1, we used a yeast-two hybrid assay to compare the 
interactions between ELMO1, ELMO1ΔC or ELMO1ΔN with RhoGQ61L (Fig. 14B).  
ELMO1 and ELMO1ΔC both interacted with RhoGQ61L and ELMO1ΔN, which has the 
region necessary for RhoGQ61L binding removed, did not interact.  The strength of the 
interaction between RhoGQ61L and ELMO1ΔC was greater than the interaction with 
ELMO1, supporting the hypothesis that an intramolecular interaction between the N- and 
C-terminal portions of ELMO1 exists.  Abolishing this interaction by removal of the C-
terminus of ELMO1 increases the ability of the N-terminus of ELMO1 to interact with 
RhoGQ61L. 
Relief of the intramolecular interaction within ELMO1 hyper-activates the 
Dock2/ELMO1 complex and increases phagocytosis 
To examine the effect of the ELMO1 intramolecular interaction within the context 
of the Dock/ELMO tetramer, we tested various ELMO1 constructs using engulfment and 
exchange assays.  Phagocytic LR73 fibroblasts transfected with GFP-ELMO1ΔN and 
Flag-Dock1 showed an increase in engulfment about 5.5-fold above basal levels – 
measured by the percent of GFP positive cells containing engulfed beads (Fig. 15A).  
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Dock1 and full-length ELMO1, on the other hand, only promoted engulfment about 2.5-
fold above basal levels, while a Dock1 + ELMO1ΔC (which does not interact with 
Dock1) only increased phagocytosis by 1.5-fold.  ELMO1 constructs transfected without 
Dock1 did not promote phagocytosis.  This increase in activity upon deletion of the N-
terminal 531 residues of ELMO1 may reflect an inhibitory effect of the intramolecular 
interaction between the N- and C-terminal portions of ELMO1.  Equivalent protein 
expression was determined by western blotting (Data not shown). 
The increase in phagocytosis caused by the ELMO1ΔN fragment could be caused 
by an increase in the ability of the Dock/ELMO complex to catalyze exchange.  To test 
the effect of ELMO1ΔN on the exchange activity of the complex, we tested the ability of 
the ELMO1 constructs to synergize with Dock1 in radioactive exchange assays.  We 
transfected 293T cells with Flag-tagged ELMO1, ELMO1ΔN and ELMO1ΔC, with and 
without Dock1, and immunoprecipitated the proteins using anti-Flag antibody.  After 
elution with the Flag peptide, we measured the amounts of protein via western blotting, 
and equalized the quantities of proteins used in a radioactive GEF assay (Fig. 15B).  We 
arbitrarily set the relative level of activity for Dock1 at 100%.  The ELMO1 fragments 
alone showed no ability to promote exchange on Rac1, neither did Dock1/ELMO1ΔC.  
Dock1/ELMO1 was capable of increased exchange activity at about 175%, however, 
Dock1/ELMO1ΔN showed an increase in exchange activity above the level of wild-type 
at about 275%.  Combined, the increase in phagocytosis and the increase in exchange 
activity suggest that the ELMO1 intramolecular interaction may serve as an inhibitory 
mechanism for Rac1 exchange. 
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The exchange activity of purified Dock2/ELMO1ΔN and Dock2/ELMO1 
complexes was tested using fluorescent-based guanine nucleotide exchange assays (see 
Fig. 16B for a gel of purified proteins showing equal concentrations of the exchange 
factors used).  Briefly, Rac1Δ177 was pre-loaded with BODIPY-FL-GDP, and the 
exchange of fluorescent nucleotide for GDP from the buffer was monitored over time as a 
decrease in fluorescence.  The data from a minimum of three assays per condition were 
fitted to a single exponential decay curve, which provided relative rates of exchange.  
Dock2/ELMO1 and Dock2/ELMO1ΔN were both efficient exchange factors for Rac1 
(Fig. 16A), and Dock2/ELMO1ΔN showed an approximately two-fold increase in the 
rate of exchange over Dock2/ELMO1 (Fig. 16C).   
RhoG-GTPγS enhances exchange activity of immunoprecipitated Dock1/ELMO1 
We suggested above that the intramolecular interaction between the N- and C-
terminal portions of ELMO1 may be an inhibitory mechanism since removal of the N-
terminus resulted in increased exchange activity and phagocytosis.  Cells must be able to 
release this inhibition for this to be a biologically-relevant mechanism.  Since RhoG is 
known to bind to the N-terminus of ELMO1 [47], activated RhoG might be the key for 
unlocking this intramolecular interaction. 
We used purified full-length, non-prenylated RhoG (C188S) as an additive in 
fluorescence-based exchange assays to test whether RhoG can affect exchange activity of 
Dock2/ELMO1 complex.  RhoG was pre-loaded with either GDP or GTPγS, a non-
hydrolysable GTP analogue, and fluorescence-based exchange assays were carried out as 
above, with the exception that RhoG was pre-incubated with Dock/ELMO where 
indicated.   
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Dock1/ELMO1 complexes were immunoprecipitated from 293T cells essentially 
as done for the radioactive GEF assays.  Flag-ELMO1 constructs were co-transfected 
with Dock1, or Flag-Dock1 was transfected alone.  Dock1, by itself, is an active 
exchange factor in vitro for Rac1, but the Dock1/ELMO1 complex is significantly more 
active than Dock1 alone (Fig. 17).  When RhoG-GDP is incubated with Dock1/ELMO1, 
there is no detectable difference in the exchange activity of the complex.  When RhoG-
GTPγS is incubated with Dock1/ELMO1, however, there is a definite increase in the 
exchange activity of the complex (Fig. 17B).  Neither Dock1 alone, nor Dock1 
complexes containing ELMO1ΔN or ELMO1GL (G72A, L77S), were activated by either 
form of RhoG (Fig. 17A and Fig. 18).  Both ELMO1ΔN and ELMO1GL are incapable of 
interacting with RhoG due to an N-terminal truncation and N-terminal point mutations, 
respectively, although interaction with Dock1 is apparently unaltered. 
RhoG-GTPγS enhances the exchange activity of purified Dock2/ELMO1 
We tested the purified Dock2/ELMO1 complex in an exchange assay with and 
without RhoG (Fig. 19A).  RhoG-GDP does not increase the rate of exchange for 
Dock2/ELMO1, but with RhoG-GTPγS, the rate is significantly increased over that of the 
complex alone.  When RhoG, in either form, is added to the Dock2/ELMO1ΔN complex, 
there is no change in the exchange activity of the complex (Fig. 19B).  The purified 
Dock2/ELMO1GL complex also showed no activation by either form of RhoG (Fig. 19C).  
While the increase in the rate of exchange seen by Dock2/ELMO1ΔN over wild-type 
complex is larger, the increase of the relative rate of exchange of the wild-type 
Dock2/ELMO1 tetramer induced by RhoG-GTPγS is statistically significant (P<0.01) as 
measured by a student’s unpaired t-test (Fig. 19E).  The purified proteins were run on a 
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Coomassie brilliant blue-stained SDS-PAGE gel, showing equivalent protein 
concentrations for the Dock2/ELMO1 complexes (Fig. 19D). 
These data suggest that the activation of the Dock2/ELMO1 complex by active 
RhoG could be a mechanism by which cells release the inhibition caused by the 
intramolecular interaction between the N- and C-terminal regions of ELMO1.  The 
binding of RhoG is known to require the N-terminus of ELMO1, and to be GTP-
dependent.  In these assays, we were able to approximate the activation of the complex 
seen with truncated ELMO1 by adding RhoG-GTPγS to wild-type Dock2/ELMO1.  
When RhoG binding was eliminated, RhoG was incapable of hyper-activating the 
complex. 
Dock2/ELMO1 phosphoinositide association 
The DHR-1 region of Dock2 is known to bind to phosphatidylinositol 3,4,5-
trisphosphate (PI(3,4,5)P3), likely through the predicted C2 domain [129].  We tested the 
lipid-binding capabilities of purified Dock2/ELMO1 complexes by incubating with 
phosphoinositide-coated beads and precipitating the bound proteins.  Consistent with 
published results, Dock2/ELMO1 bound to PI(3,4,5)P3, and not to other 
phosphoinositides (Fig. 20A).  Of interest, when we compared the binding of 
Dock2/ELMO1 and Dock2/ELMO1ΔN to PI(3,4,5)P3, we found that noticeably more 
Dock2/ELMO1ΔN bound to the PI(3,4,5)P3 beads than the wild-type tetramer (Fig. 20B).   
The contribution of the ELMO1 and ELMO1ΔN molecules to PI(3,4,5)P3 binding 
by the Dock2/ELMO1 complexes was examined by assaying the ability of bacterially-
purified ELMO1 and ELMO1ΔN to interact with PI(3,4,5)P3.  Increasing concentrations 
of purified ELMO1 proteins were titrated into a cuvette containing fluorescently-labeled 
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PI(3,4,5)P3 and the change in fluorescence polarization was monitored as a direct 
measure of binding to the phosphoinositide.  Neither ELMO1 nor ELMO1ΔN showed 
appreciable binding when compared to a control protein, a GST-tagged PH domain from 
Grp1 (Fig. 20C).  This suggests that the increased binding to PI(3,4,5)P3 by the 
Dock2/ELMO1ΔN tetramer is not a result of ELMO1ΔN interaction with PI(3,4,5)P3.  
This does not discount, however, the possibility that deletion of the N-terminus of 
ELMO1 artificially exposes a region of Dock2 which can bind phosphoinositides.  
Potentially, though, the removal of the intramolecular interaction within ELMO1 by 
deletion of the N-terminus may be responsible for a change in the conformation of the 
tetramer, which is then capable of an increased interaction with PI(3,4,5)P3 through the 
C2 domains within the Dock2 molecules. 
Discussion 
Figure 19 presents a model of Dock2/ELMO1 regulation by RhoG.  In this model, 
the cytoplasmic form of the Dock2/ELMO1 heterotetramer is in an inhibited state.  
Dock2 and ELMO1 are bound via approximately two interfaces within the C-terminal 
region of ELMO1 and the N-terminal region of Dock2.  The two Dock2 molecules are 
tightly associated via a dimerization interface located within the DHR-2 regions of the 
two proteins, potentially via the putative coiled-coil region (Fig. 1).  Each ELMO1 
molecule is in the inhibitory state, where the N-terminal region is bound to the C-terminal 
region.  As a result of this series of interactions, the PH domains of the ELMO1 
molecules are unable to stabilize nucleotide-free Rac in the binding pocket provided by 
the two Dock2 molecules. 
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Upon activation of RhoG, the N-terminal regions of the ELMO1 molecules bind 
to the activated GTPase, translocating the Dock2/ELMO1 complex to the plasma 
membrane where the substrate Rac molecules are located.  The binding of activated 
RhoG to the N-terminus of ELMO1 releases the inhibited conformation and allows the 
PH domains to move into a position where they can stabilize the nucleotide-free 
transition state of the Rac molecule.  This rearrangement of ELMO1 spurs a change in the 
conformation of the Dock2 molecules as well, allowing the C2 domains to contact 
PI(3,4,5)P3 at the membrane, stabilizing the complex in this position. 
This model compiles a body of preexisting literature with the results that we have 
presented in both chapters 2 and 3.  Some of the ideas presented in that model need 
testing to allow us to confirm or adapt the model.  A stepwise analysis of the model and 
the relevant results that the model is based on follows: 
1) Pre-activation conformation of the model (Fig. 21A) 
a.  The interactions between Dock2 and ELMO1 have been presented in the 
literature [41,42,47,48,71,74].  The overall composition of the molecule as 
a 2:2 heterotetramer comes from the light scattering analysis of the 
Dock2/ELMO1 complex (Fig. 11). 
b. The suggested dimerization interface between the two Dock2 molecules is 
predicted based on evidence in the literature [44,118] and our own 
analysis of a potential coiled-coil region within the DHR-2 domain (Fig. 
1).   
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c. The inhibited conformation of ELMO1 was analyzed in our results using 
SEC, light scattering, immunoprecipitations and yeast two-hybrid assays 
(Fig. 4, 13-14).   
d. The positioning of the PH domains as inaccessible to stabilize Rac in the 
binding pocket is based on our observation that deletion of the N-terminus 
of ELMO1 enhances exchange activity (Fig. 15), and preexisting 
knowledge that the PH domain of ELMO1 can bind to a Dock/Rac 
complex and can increase the exchange rate of the complex [49].  
Combining those observations, the best-fit model to our data would place 
the PH domain in a position where it is not accessible to enhance 
exchange activity while the ELMO1 inhibitory intramolecular interaction 
is in place. 
2) Active conformation (Fig 19B) 
a. Localization of the Dock/ELMO complex at the membrane via RhoG 
binding to ELMO proteins has been described in the literature [47,74]. 
b. We have no direct evidence for the stoichiometry of the RhoG:tetramer 
interaction, but have drawn the model with two molecules of RhoG per 
tetramer based on the based on evidence that purified, monomeric ELMO 
proteins can interact with activated RhoG (Fig. 5-7).  This suggests that 
each molecule of ELMO1 in the tetramer would have the capability to 
bind RhoG. 
c. Interruption of the ELMO1 intramolecular interaction by RhoG is based 
on our data that an intramolecular interaction exists (Fig. 4, 13-14), as well 
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as our exchange assays showing that active RhoG is capable of activating 
the Dock2/ELMO1 complex similarly to the activation seen by truncating 
the N-terminus of ELMO1 (Fig. 19).  This activation of Dock2/ELMO1 
by RhoG is dependent upon its ability to interact with the N-terminus of 
ELMO1 (Fig. 19). 
d. Exposure of the PH domains to allow stabilization of Rac in the binding 
pocket is based on our data showing the increase in activity upon deletion 
of the N-terminal region of ELMO1 (Fig. 15-17).  This fragment is 
primarily composed of the PH domain and the C-terminal Dock-
interacting residues (Fig 1).  The explanation for the increase in activity 
could be from a change in the overall conformation of the Dock2/ELMO1 
tetramer, allowing increased activity – perhaps through changes in the 
binding pocket.  However, evidence for the contribution of the PH 
domains to the activity of the complex has been published [49], and this 
seems to be the best explanation with the data available.  Experiments to 
test this concept have been described in chapter 4. 
e. Movement of the C2 domains to allow binding to PI(3,4,5)P3 at the 
membrane is based upon our data that more Dock2/ELMO1ΔN tetramer 
binds to PI(3,4,5)P3 beads than the wild-type tetramer (Fig 18B).  At least 
two explanations can explain this data.  Deletion of the N-terminus of 
ELMO1 may simply cause an area of Dock2 to be exposed that normally 
would not be exposed in the tetramer, and the increase in lipid-binding 
could simply be a non-specific effect.  The specificity of binding shown 
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by both mutant and wild-type tetramer (Fig. 20A) would suggest that this 
is not the case, but we cannot discount the possibility.  We would suggest 
that the deletion of the N-terminus of ELMO1 (or, as in our model, the 
binding of RhoG to the N-terminus), instead, causes a conformational 
change within the tetramer that moves the C2 domain to a configuration 
that allows easier access to lipids for binding.  This would be consistent 
with the RhoG localization of the tetramer to the membrane, as the C2 
domain has been shown to be instrumental in membrane localization as 
well [38]. 
The model provides an overview for how RhoG directly regulates the exchange 
capacity of the Dock/ELMO tetramer through binding to ELMO1.  The results presented 
give us a clearer understanding of what contributions ELMO proteins make to the 
exchange activity of the Dock/ELMO bipartite GEF. 
 
 
 
 Figure 13: ELMO1 can interact with itself in cells. 
A,B) The indicated constructs of Flag and GFP-tagged ELMO1 were co-transfected into 293T cells.  
Lysates were precipitated with anti-Flag antibody and co-precipitating GFP-tagged proteins were assessed 
by immunoblotting.  The failure of Flag-ELMO1ΔN to precipitate GFP-tagged ELMO1ΔC in panel B is 
unclear, as the interaction is obvious when the precipitation was done in the reverse direction.  *These 
experiments were performed by Colin deBakker, Ravichandran Lab, University of Virginia. 
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 Figure 14: The N-and C-terminal regions of ELMO1 interact 
A) Yeast two-hybrid assay.  The N- and C-terminal portions of ELMO1 preferentially interact relative to 
other combinations.  The interaction is comparable to the interaction between ELMO1ΔC and RhoG.  The 
HF7C yeast strain was transformed with the indicated constructs using a lithium acetate-based 
transformation protocol.  Colonies were plated in decreasing concentrations on selection media lacking 
histidine, tryptophan and leucine.  B) Removing the C-terminus of ELMO1 increases the interaction 
between ELMO1 and RhoG.  The HF7C yeast strain was transformed with the indicated constructs and 
plated on increasingly selective media.  *These experiments were performed by Colin deBakker, 
Ravichandran Lab, University of Virginia. 
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 Figure 15: Deletion of the N-terminus of ELMO1 hyper-activates the Dock1/ELMO1 complex. 
A) LR73 cells were transiently transfected with the indicated ELMO1 constructs (1.0 µg/well) with or 
without Flag-Dock1 (1.2 µg/well) in triplicate.  Empty Flag vector was added if necessary to ensure equal 
total plasmid concentrations were used for transfection in each condition.  The phagocytosis, as measured 
as the fraction of GFP positive cells with engulfed particles, is shown.  GFP mean fluorescence intensity 
(MFI) was matched between the different constructs and cells with comparable MFI were analyzed 
throughout the experiment.  Data are representative of at least 5 independent experiments. 
B) 293T cells were transiently transfected with the indicated plasmids encoding various constructs of 
ELMO1, either alone or co-transfected with Dock1.  After 48 hours, Flag immunoprecipitations were 
performed and the samples were tested in an in vitro GEF assay using bacterially produced Rac1 pre-
loaded with 32P-GTP as a substrate.  The activity with Dock1 alone was arbitrarily set at 100%.  
Comparable expression of the transfected proteins was confirmed by immunoblotting (not shown).  *These 
experiments were performed by Colin deBakker, Ravichandran Lab, University of Virginia. 
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 Figure 16: Deletion of the N-terminus of ELMO1 hyper-activates the Dock2/ELMO1 complex. 
A) Purified Dock2/ELMO1 (D2/E1) and Dock2/ELMO1ΔN (D2/E1ΔN) complexes (15 nM) were tested 
for exchange activity using a fluorescence-based assay.  Bacterially purified Rac1Δ177 (150 nM) was pre-
loaded with BODIPY-FL-GDP.  As the BODIPY-FL-GDP is exchanged for GDP the loss of fluorescence 
is measured.  Individual curves shown are representative of 3-4 independent experiments.  B) Equal 
amounts of Dock2/ELMO1 and Dock2/ELMO1ΔN were run on an SDS-PAGE gel and visualized with 
Coomassie brilliant blue staining to show purity and equivalent concentration.  C) Relative exchange rates 
determined from fluorescence-based assays as in (A) with a minimum of three independent experiments per 
condition. 
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 Figure 17: Active RhoG enhances the exchange activity of the Dock1/ELMO1 complex. 
A) Active RhoG does not enhance the exchange activity of Dock1.  Flag-Dock1 was expressed in 293T 
cells.  Lysates were precipitated with anti-Flag antibody-conjugated beads and proteins were eluted using 
Flag peptide.  Proteins were quantitated by immunoblotting and equivalent amounts were used in each 
assay.  Exchange assays were performed as in Figure 14 with Rac1(C189S) pre-loaded with BODIPY-FL-
GDP, with a minimum of three independent experiments per condition.  Where indicated, RhoG (final 
concentration: 10 µM), pre-loaded with GDP or GTPγS was pre-incubated with Dock1.  Left panel shows 
representative curves, right panel shows relative rates of exchange.  B) Active RhoG enhances the 
exchange activity of Dock1/ELMO1.  Flag-tagged ELMO1 was co-expressed with Dock1 in 293T cells and 
was immunoprecipitated as above.  Exchange activity was measured as above.  Left panel shows 
representative curves, right panel shows relative rates of exchange.  * denotes the difference in the means is 
statistically significant (P < 0.05) as determined by a student’s unpaired t-test assuming equal variances. 
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 Figure 18: Active RhoG requires the N-terminus of ELMO1 to enhance the exchange activity of the 
Dock1/ELMO1 complex. 
A, B) Indicated proteins were immunoprecipitated from 293T cells as described in Figure 15.  Exchange 
assays were carried out as indicated in Figure 15.  Left panels show representative curves and the right 
panels show relative rates of exchange. 
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 Figure 19: B-D.  Active RhoG requires the N-terminus of ELMO1 to enhance the exchange activity of 
the Dock2/ELMO1 complex. 
A-C) Active RhoG enhances exchange activity of Dock2/ELMO1, but does not activate 
Dock2/ELMO1ARM or Dock2/ELMO1ΔN.  Recombinant Dock2/ELMO1 complexes were purified from 
insect cells, and used at a concentration of 15 nM.  Rac1Δ177 (150 nM) and RhoG (10 µM) were purified 
from bacteria and preloaded as in figures 14 and 15.  Curves shown are representative of 3-5 independent 
experiments.  D) Coomassie brilliant blue-stained SDS-PAGE gels of purified protein used in (A-C).  Left 
panel shows equal amounts of different Dock2/ELMO1 complexes.  Right two panels show purified RhoG 
and Rac1.  E) Relative rates of exchange for various Dock2/ELMO1 complexes +/- RhoG.  Each rate was 
calculated from 3-5 independent experiments.  ** denotes p < 0.01 when comparing the rates between 
Dock2/ELMO1 and Dock2/ELMO1 + RhoG-GTPγS, as determined by an unpaired t-test assuming equal 
variances. 
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 Figure 20: Dock2/ELMO1ΔN specifically binds more PI(3,4,5)P3 than Dock2/ELMO1. 
A) Beads modified with indicated phospholipids were incubated with either Dock2/ELMO1 (wt) or 
Dock2/ELMO1ΔN (ΔN) as indicated.  Bound proteins were analyzed by SDS-PAGE and immunoblotting 
for His-Dock2.  B) Varying amounts of total D2/E1 or D2/E1ΔN were incubated with PI(3,4,5)P3 beads.  
Bound proteins were analyzed as in (A).  C) Binding of ELMO1 and ELMO1ΔN to BODIPY-FL labeled 
PI(3,4,5)P3 was monitored by change in polarization.  The GST-tagged PH domain of Grp1 was used as a 
control for binding.  No binding curve could be accurately fitted to ELMO1 and ELMO1ΔN data. 
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 Figure 21: Model of direct activation of the Dock/ELMO tetramer by RhoG. 
A) Cytoplasmic Dock/ELMO tetramer.  Dock protein in blue, ELMO protein in red, Rac1 in yellow, RhoG 
in green.  The Dock protein SH3 domain and N-terminal residues bind the C-terminal region of the ELMO 
protein.  The N- and C-terminal regions of ELMO1 interact to inhibit the Dock/ELMO complex.  RhoG-
GDP does not activate Dock/ELMO.  B) Membrane-associated Dock/ELMO tetramer.  RhoG-GTP binds 
the N-terminus of the ELMO protein to release inhibitory conformation, and localizes the Dock/ELMO 
complex to the membrane, allowing exchange activity on membrane-bound Rac.  The PH domain of the 
ELMO protein stabilizes nucleotide-free Rac in the binding pocket of the Dock/ELMO tetramer, enhancing 
exchange activity.  The C2 domain of the Dock protein can bind to PI(3,4,5)P3 (yellow) at the membrane. 
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CHAPTER 4 – CONCLUSIONS AND FUTURE DIRECTIONS 
Conclusions 
The Dock family of proteins is rapidly growing in recognized importance within a 
variety of cellular signaling pathways.  Understanding the mechanisms of function and 
regulation of these relatively new, non-Dbl-family GEFs will lead to insight on potential 
therapies for diseases in which these proteins play a key role. 
We have demonstrated that Dock1 and Dock2 associate with ELMO proteins in a 
seemingly obligatory complex.  The Dock/ELMO complex functions as a 2:2 
heterotetramer, binding to and activating one molecule of Rac1, Rac2 or Rac3 at a time.  
The size of this complex and the existence of the functional unit as a heterotetramer leads 
us to question how these proteins function together to promote exchange on Rho-family 
GTPases.   
Examination of the effect that ELMO1 had upon the activity of the complex led to 
data showing that ELMO1 had a direct effect on the activity of the Dock/ELMO 
complex.  Upon further examination, we found that RhoG was capable of modulating this 
direct effect upon the exchange activity of the Dock/ELMO complex, providing a new 
mode of regulation of Dock/ELMO complexes by RhoG. 
A model, combining research presented here and other published data, provides 
an overview for the regulation of the Dock/ELMO complex by RhoG.  As presented, the 
Dock/ELMO complex exists in the cytoplasm in a closed state, with the two ELMO1 
molecules “closed” through the interaction between the N- and C-terminal regions of the 
protein.  Upon activation of RhoG, the ELMO1 molecules are now able to interact with 
RhoG and the Dock/ELMO complex is localized to the membrane by this interaction.  
RhoG binds to the N-terminus of ELMO1, interrupting the N- and C-terminal interaction 
within ELMO1, allowing the Dock/ELMO complex to shift conformation.  The PH 
domains of the ELMO1 molecules are now able to shift into position to stabilize Rac1 in 
the nucleotide-free transition state.  The entire Dock/ELMO complex may also shift 
conformation in two ways: 1) the active site may become more accessible upon the 
release of the inhibitory interaction within ELMO1, and 2) the C2 domains of the Dock 
proteins may shift in relation to the tetramer to allow association with the membrane 
through binding to PI(3,4,5)P3 (Fig. 21). 
Interestingly, a model for the regulation of Dock11, which does not bind ELMO 
proteins, shows some striking similarities to our model with the binding of an activated 
GTPase to increase the exchange activity of Dock11.  Briefly, Dock11 is capable of 
binding activated Cdc42, as well as being an exchange factor for Cdc42.  Lin, et al. 
proposed that the N-terminus of Dock11 interacts with the DHR-1 region, and Dock11 
has limited GEF activity in this conformation.  Upon activation of Cdc42, the active 
GTPase binds to the N-terminus of Dock11 and this increases the exchange activity [88].  
It will be interesting to see if the common threads in the two models might reflect a 
common mechanism of activation and even translocation for the Dock proteins.  The idea 
that the PH domain in the N-terminus of the Dock D subfamily may be acting similarly to 
the PH domain provided by ELMO proteins for the Dock A and Dock B subfamilies has 
been suggested previously [41].  Although no significant sequence homology would 
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suggest it, is it possible that the N-terminal areas of the Dock D and perhaps even Dock C 
proteins have evolved to replace ELMO proteins in the mechanism of activation, or vice 
versa? 
Future work that will help refine this model of activation of Dock/ELMO by the 
interaction of RhoG with ELMO proteins is presented in the following sections. 
Future Directions 
Testing of PH-domain enhancement of Dock2/ELMO1 Rac1 activation 
One assumption made in the model presented (Fig. 21) is that the previously-
reported enhancement of exchange activity by the PH domain is responsible for at least 
some of the activation seen when RhoG binds to ELMO1.  We assumed that 1) the PH 
domain is not available to stabilize the nucleotide-free transition state of Rac1 while the 
N- and C-terminal regions of ELMO1 are bound in the inhibitory interaction and 2) the 
relief of this inhibition allows enhancement of exchange activity by allowing the PH 
domain access to the binding site to stabilize the nucleotide-free transition state. 
One way to test this idea would be to make mutant forms of ELMO1 to purify in a 
complex with Dock2 in insect cells.  There are three known mutations within ELMO1 
which abrogate the interaction between the isolated PH domain and a Dock/Rac complex 
[41].  W665A, G559A and FRK?AAA (662-664) mutations within the PH domain are 
all capable of interfering with this interaction.  If these mutations were introduced into 
both ELMO1 (wt) and ELMO1ΔN, the resulting Dock2/ELMO1 complexes could be 
purified and tested for both the activation of Dock2/ELMO1 via truncation of the N-
terminus and activation via binding of RhoG.  In either case, if the contribution of the PH 
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domain stabilizing the nucleotide-free transition state is what is responsible for the 
activation of the Dock/ELMO exchange activity, these mutants should have no more 
activity that wild-type protein. 
Test the membrane contribution of the activation of Dock2/ELMO1 by RhoG 
In the exchange assays presented in chapters 2 and 3, the contribution of the 
membrane to the interactions and activation of the Dock/ELMO complex was not tested.  
In our assays, the wild-type Dock2/ELMO1 was an efficient exchange factor without any 
activated RhoG present, and the relatively modest enhancement to the rate upon addition 
of active RhoG may only be indicative of the partial effect that RhoG has on the 
Dock/ELMO complex.  It is possible that the increase in exchange activity upon binding 
of RhoG may be much greater than that seen in assays without a membrane present. 
To address this question, exchange assays using lipidated Rac1 and lipidated 
RhoG incorporated into lipid vesicles would provide a way to determine the contribution 
of the membrane.  Lipidated forms of GTPases can be made using baculovirus expression 
systems, and can be incorporated into reconstituted lipid vesicles after purification.  The 
assays would examine the effects of various combinations of lipidated and non-lipidated 
Rac1 and/or RhoG.  The specific contributions to activity could be clearly defined using 
the Rac1 and RhoG combinations as well as the Dock2/ELMO1 mutants which are 
incapable of interacting with RhoG (ELMO1ΔN and ELMO1GL). 
Crystallization of Dock2/ELMO1 complexes 
The ability to purify a stable Dock2/ELMO1 complex to near homogeneity ant to 
a relatively high concentration (up to ~40 mg/ml) provides the opportunity to attempt 
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crystallization of the complex for X-ray crystallographic structure determination.  A 
variety of commercially-available screens have been used to set up crystallization trials 
for the Dock2/ELMO1 (at 12 mg/ml) and a Dock2/ELMO1/Rac1Δ177 (17 mg/ml) 
trimeric complex, with no potential crystal conditions yet.  Obviously, a great many more 
crystallization conditions can be tried, at much higher concentrations than used before. 
One problem encountered while trying to crystallize this complex will be the 
relative concentration of the protein.  Even at a concentration of 40 mg/ml, the tetramer 
molar concentration is only approximately 67 µM.  This could present difficulties in 
obtaining crystals.  Complexes that would be of interest to crystallize would include 
Dock2/ELMO1 (wt), Dock2/ELMO1/Rac1, Dock2/ELMO1ΔN, Dock2/ELMO1ΔN/Rac1 
and even a structure of ELMO1 without a Dock protein could provide useful information, 
with or without RhoG. 
ELMO1 may show homology to the formin protein GTPase binding domain and the 
Diaphanous autoregulatory domain. 
After several rounds of psi-BLAST [100] analysis of the mouse ELMO1 
sequence, the N-terminus of ELMO1 is picked out as homologous to several different 
formin homology 2 (FH2)-domain containing proteins, including FHOS, a formin protein 
that is enriched in the spleen [120].  Formins contain multiple domains and govern 
dynamic remodeling of the cytoskeleton [130].  Interestingly, formins are known to have 
an autoinhibitory interaction between the N- and C-terminal regions of the proteins, 
mediated by a C-terminally located diaphanous autoregulatory domain (DAD) and an N-
terminally located GTPase binding domain (GBD).  The homology between the N-
terminus of ELMO1 and FHOS detected by psi-BLAST resides within the N-terminal 
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region of FHOS, which is where the predicted GBD for that protein lies [130].  FHOS has 
been shown to interact with Rac1, dependent upon the PBR of Rac1.  The predicted 
homology of ELMO1 to the formin proteins suggests, especially since the homology lies 
within the GBD of the formins, that the mechanism of the ELMO1 N- and C-terminal 
interaction may be similar to that of the formin autoinhibitory interactions.  Accordingly, 
there is a region within the C-terminus of ELMO1 which loosely corresponds to the DAD 
motif of the formins. 
Structures are available showing the binding of RhoC to the formin protein, 
mDia1, as well as showing the DAD bound to mDia1.  With an in-depth sequence 
analysis between ELMO1 and formin proteins within the regions of homology, it should 
be possible to design mutants to test if this homology between ELMO1 and the formins 
carries over to the GBD-DAD inhibitory interaction.  By designing mutants in the DAD-
like region of ELMO1 and/or in the GBD-like region, we may be able to interfere with 
the inhibitory interaction within ELMO1 as well as with the RhoG binding capabilities.  
A point mutant which abrogates the ELMO1 intramolecular interaction would be very 
useful in studying how the ELMO1 molecule affects the exchange activity of the 
Dock/ELMO complex, and would allow us to refine our model further. 
Analysis of Rac1 binding to ELMO1 
In chapter 2, we identified an interaction between GTPγS-bound Rac1(C189S) 
and ELMO1 in addition to the commonly reported RhoG-GTPγS interaction.  In a few 
different publications, the interaction of ELMO1 with RhoG has been reported, but 
interactions between ELMO1 and Rac1 have been tested for and not detected [40,47].  To 
understand the interaction between ELMO1 and Rac1, a few different experiments are 
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possible.  First, we need to determine if the RhoG and Rac1 binding sites are the same.  
Through use of truncated and mutant ELMO1 constructs, we should be able to determine 
the general region to which Rac1 is binding.  ELMO1ΔN and ELMO1 (wt) can both be 
purified from bacteria, and ELMO1ΔC the ELMO1GL mutant should be able to be 
purified as well.  Between these constructs we should be able to identify if Rac1 is 
binding to the N- or C-terminus of ELMO1.  If Rac1 is binding to the N-terminus of 
ELMO1, we can use the ELMO1GL mutant to determine if Rac1 is binding in the same 
region as RhoG.  If Rac1 is binding to the same site on ELMO1 as RhoG, it is likely that 
the similarities between the two proteins are simply allowing Rac1 to bind in an artificial, 
in vitro setting.  If, however, Rac1 binds to the C-terminus of ELMO1, this would 
suggest a potentially biologically-relevant association.  As mentioned in chapter 2, the 
activation of Rac1 could allow Rac1-GTP to bind to ELMO1, perhaps stabilizing the 
Dock/ELMO complex in its enhanced-activity conformation in a positive feed-forward 
loop, similar to the reported cases for Ras-Sos interaction and Cdc42-Dock11 
[88,123,124]. 
Summary 
The model of how RhoG regulates the activity of the Dock/ELMO heterotetramer 
through interaction with ELMO proteins is a scaffold on which to build a more thorough 
understanding of how the Dock-family of exchange factors catalyze the exchange of 
nucleotide on Rho GTPases, and of how these proteins are regulated.  These studies, 
designed with the model in mind, will allow us to add detail to the mechanisms behind 
the Dock-family GEFs so that we can further define its role in cellular signaling and 
disease. 
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